[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1221
6. Romano G, Giordano A: Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle; 2008 Dec;7(23):3664-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases.
  • The so-called Cdk9-related pathway comprises two Cdk9 isoforms (Cdk9-42 and Cdk9-55), cyclin T1, cyclin T2a, cyclin T2b and cyclin K.
  • Through the control of RNA polII-mediated gene expression, the Cdk9-related pathway performs an important role in several biological processes, such as cell growth, proliferation, protection from apoptosis and differentiation.
  • A deregulation in the Cdk9-related pathway is associated with various types of human malignancies and cardiomyocytes hypertrophy.
  • On these grounds, the characterization of Cdk9-related pathway deregulation might have a two-fold purpose:.
  • (1) the development of novel kinase inhibitors for the treatment of cancer, AIDS and cardiac hypertrophy and (2) a better understanding of the pathogenesis and progression of these maladies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029809.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.22 / Cyclin-Dependent Kinase 9
  • [Number-of-references] 79
  •  go-up   go-down


7. Aiello-Laws L, Rutledge DN: Management of adult patients receiving intraventricular chemotherapy for the treatment of leptomeningeal metastasis. Clin J Oncol Nurs; 2008 Jun;12(3):429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer in the central nervous system can arise from a primary brain tumor and metastasize to the brain or to the leptomeninges, leading to leptomeningeal metastasis (LM).
  • Nursing care of patients with LM requires an understanding of neurologic anatomy and physiology, along with associated treatments and complications.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Blepharoptosis / etiology. Brain Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / nursing. Carcinoma / secondary. Drug Compounding. Drug Monitoring / nursing. Evidence-Based Medicine. Fatal Outcome. Humans. Low Back Pain / etiology. Lymphoma, AIDS-Related / complications. Male. Muscle Weakness / etiology. Nurse's Role. Nursing Assessment. Practice Guidelines as Topic

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515241.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  • [Number-of-references] 30
  •  go-up   go-down


8. Granström G: Craniofacial osseointegration. Oral Dis; 2007 May;13(3):261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Further applications of osseointegration in the craniofacial field is related to the rehabilitation of patients with defects from cancer therapy, malformations, traumatic amputations and burns.
  • Other aspects are related to osseointegration in children.
  • [MeSH-minor] Adult. Bone and Bones / physiology. Bone and Bones / radiation effects. Child. Cranial Irradiation / adverse effects. Ear, External. Hearing Aids. Humans. Nose. Orbital Implants

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448206.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 69
  •  go-up   go-down


9. McLaughlin KA, Wucherpfennig KW: B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol; 2008;98:121-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases.

  • Genetic Alliance. consumer health - Demyelinating Diseases.
  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772005.001).
  • [ISSN] 0065-2776
  • [Journal-full-title] Advances in immunology
  • [ISO-abbreviation] Adv. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI045757
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Autoantibodies; 0 / Cytokines; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 168
  • [Other-IDs] NLM/ NIHMS710407; NLM/ PMC4520528
  •  go-up   go-down


10. Lim ST, Levine AM: Non-AIDS-Defining Cancers and HIV Infection. Curr Infect Dis Rep; 2005 May;7(3):227-234
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-AIDS-Defining Cancers and HIV Infection.
  • With fewer patients now succumbing to infectious complications of AIDS, other HIV-related morbidities such as malignancies have become increasingly important.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • However, the types of cancer observed at an increased frequency and the relative risks reported vary widely among studies.
  • Although immunosuppression is consistently associated with an increased risk of AIDS-related malignancies, the role of immunosuppression in the pathogenesis of non-AIDS- defining cancers is controversial.
  • Although data regarding the optimal management of these cancers are lacking, current studies suggest that patients with HIV-associated malignancies should be treated with similar approaches to those of their counterparts in the general population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 15847726.001).
  • [ISSN] 1523-3847
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Volkow P, Zinser JW, Correa-Rotter R: Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC Nephrol; 2007;8:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Imatinib is a tyrosine-kinase inhibitor; for which there is limited information regarding its effects on AIDS Kaposi's sarcoma and none in patients with transplant-associated Kaposi's sarcoma.
  • Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi's sarcoma associated with renal graft.
  • CASE PRESENTATION: Here we report a case of an 80 year old male, who developed Kaposi's Sarcoma nine months after receiving a living non-related donor kidney transplant at age 74.
  • CONCLUSION: The lack of benefit and severe toxicity associated with the use of Imatinib in this patient should alert clinicians of potentially adverse consequence of its use in patients with transplant associated Kaposi's sarcoma.
  • On the other hand the positive response seen in this patient to Sirolimus even after a long evolution of Kaposi's sarcoma, multiple chemotherapy regimens and extensive cutaneous disease further suggest it therapeutical utility for transplant associated Kaposi's sarcoma.
  • [MeSH-minor] Aged, 80 and over. Benzamides. Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Imatinib Mesylate. Immunohistochemistry. Kidney Failure, Chronic / diagnosis. Kidney Failure, Chronic / surgery. Male. Neoplasm Staging. Retreatment. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1995 Mar;146(3):727-34 [7887453.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):332-4 [7547414.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1999-2008 [8669484.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):964-6 [15848592.001]
  • [Cites] Int J STD AIDS. 2006 Sep;17(9):571-8 [16942647.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2592-7 [15197801.001]
  • [Cites] J Invest Dermatol. 1990 Dec;95(6 Suppl):176S-179S [2258634.001]
  • [Cites] Rev Med Interne. 1990 Jul-Aug;11(4):322-4 [2096440.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1779-83 [8348508.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):890-4 [8408835.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • (PMID = 17386117.001).
  • [ISSN] 1471-2369
  • [Journal-full-title] BMC nephrology
  • [ISO-abbreviation] BMC Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1852096
  •  go-up   go-down


12. Stalmeier PF, Roosmalen MS: Concise evaluation of decision aids. Patient Educ Couns; 2009 Jan;74(1):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concise evaluation of decision aids.
  • OBJECTIVE: Decision aids purport to help patients make treatment related choices.
  • Several instruments exist to evaluate decision aids.
  • METHODS: Two different decision aids were randomized in patients at high risk for breast and ovarian cancer.
  • Three factors were identified related to Information, Well-being and Decision Making.
  • CONCLUSION: Four single items, 'the amount of information received for decision making,' 'strength of preference,' 'I weighed the pros and cons,' and 'General Health,' were adequately responsive to the decision aids.
  • PRACTICE IMPLICATIONS: These items might be considered for inclusion in questionnaires to evaluate decision aids.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775622.001).
  • [ISSN] 0738-3991
  • [Journal-full-title] Patient education and counseling
  • [ISO-abbreviation] Patient Educ Couns
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


13. Ozcakir A, Uncu Y, Sadikoglu G, Ercan I, Bilgel N: Students' views about doctor-patient communication, chronic diseases and death. Educ Health (Abingdon); 2008 Mar;21(1):149
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our secondary objective was to delineate the educational needs related to this field.
  • According to the students, the most fatal diseases were cancer and AIDS.


1
Advertisement
4. Broder S: The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res; 2010 Jan;85(1):1-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.
  • In the last 25 years, HIV-1, the retrovirus responsible for the acquired immunodeficiency syndrome (AIDS), has gone from being an "inherently untreatable" infectious agent to one eminently susceptible to a range of approved therapies.
  • During a five-year period, starting in the mid-1980s, my group at the National Cancer Institute played a role in the discovery and development of the first generation of antiretroviral agents, starting in 1985 with Retrovir (zidovudine, AZT) in a collaboration with scientists at the Burroughs-Wellcome Company (now GlaxoSmithKline).
  • We focused on AZT and related congeners in the dideoxynucleoside family of nucleoside reverse transcriptase inhibitors (NRTIs), taking them from the laboratory to the clinic in response to the pandemic of AIDS, then a terrifying and lethal disease.
  • This has special implications within the classic boundaries of public health around the world, but at the same time in certain regions may also affect a cycle of economic and civil instability in which HIV-1/AIDS is both cause and consequence.
  • The current science will lead to new therapeutic strategies with far-reaching implications in the HIV-1/AIDS pandemic.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Non-ARV Adverse Events .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • [Cites] Annu Rev Immunol. 2008;26:317-53 [18304004.001]
  • [Cites] N Engl J Med. 2008 Apr 10;358(15):1590-602 [18403767.001]
  • [Cites] J Infect Dis. 2008 May 1;197(9):1324-32 [18422445.001]
  • [Cites] Lancet. 2008 Apr 26;371(9622):1417-26 [18387667.001]
  • [Cites] PLoS One. 2008;3(5):e2077 [18461185.001]
  • [Cites] Lancet. 2008 May 10;371(9624):1558-9 [18468529.001]
  • [Cites] Lancet. 2008 May 10;371(9624):1603-11 [18468544.001]
  • [Cites] N Engl J Med. 2008 May 15;358(20):2170-2 [18480210.001]
  • [Cites] Vaccine. 2008 Jun 6;26(24):2951-65 [18325640.001]
  • [Cites] Cell Host Microbe. 2008 Jun 12;3(6):388-98 [18541215.001]
  • [Cites] Clin Infect Dis. 2008 Jul 15;47(2):266-85 [18549313.001]
  • [Cites] Microbiol Immunol. 2008 Jun;52(6):318-25 [18577167.001]
  • [Cites] N Engl J Med. 2008 Jul 10;359(2):119-29 [18525035.001]
  • [Cites] Lancet. 2008 Jul 26;372(9635):293-9 [18657708.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Mar;25(3):343-5 [19327053.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Mar;4(2):82-7 [19339945.001]
  • [Cites] HIV Med. 2009 May;10(5):290-301 [19220493.001]
  • [Cites] Microbes Infect. 2009 Apr;11(4):500-8 [19233310.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7 [2430286.001]
  • [Cites] Lancet. 1987 Jan 17;1(8525):132-5 [2879972.001]
  • [Cites] N Engl J Med. 1987 Feb 26;316(9):557-64 [3543683.001]
  • [Cites] Nature. 1987 Feb 26-Mar 4;325(6107):773-8 [2434858.001]
  • [Cites] Clin Pharmacol Ther. 1987 Apr;41(4):407-12 [3549120.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):2033-7 [2436223.001]
  • [Cites] J Virol. 1987 May;61(5):1690-4 [2437321.001]
  • [Cites] Biochem Pharmacol. 1987 Jun 1;36(11):1765-8 [3107569.001]
  • [Cites] N Engl J Med. 1987 Jul 23;317(4):185-91 [3299089.001]
  • [Cites] Lancet. 1988 Jan 16;1(8577):76-81 [2891981.001]
  • [Cites] Science. 1988 Jan 15;239(4837):295-7 [3336784.001]
  • [Cites] AIDS Res Hum Retroviruses. 1988 Apr;4(2):107-13 [2835072.001]
  • [Cites] Public Health Rep. 1988 May-Jun;103(3):224-9 [3131811.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90 [3290901.001]
  • [Cites] N Engl J Med. 2009 Apr 30;360(18):1897-9 [19339713.001]
  • [Cites] Lancet. 2009 Jul 18;374(9685):260-3 [19303630.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):515-9 [19626114.001]
  • [Cites] Nat Med. 2009 Aug;15(8):871-2 [19648927.001]
  • [Cites] J Clin Microbiol. 2009 Nov;47(11):3763-4 [19759232.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):210-31 [19616029.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):232-40 [19665489.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):91-100 [19683546.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):75-90 [19781578.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):119-41 [19782103.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):286-94 [19808057.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):34-8 [19854224.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):142-58 [19874851.001]
  • [Cites] Antiviral Res. 2010 Jan;85(1):39-58 [19887088.001]
  • [Cites] Ann N Y Acad Sci. 1990;616:328-43 [2078027.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(6):585-92 [1673712.001]
  • [Cites] Mol Pharmacol. 1991 Jul;40(1):118-24 [1677450.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Feb;6(2):162-70 [8433280.001]
  • [Cites] J Clin Microbiol. 1994 Feb;32(2):292-300 [8150937.001]
  • [Cites] J Pediatr Psychol. 1994 Feb;19(1):47-61 [8151495.001]
  • [Cites] AIDS. 1993 Nov;7 Suppl 2:S29-34 [8161443.001]
  • [Cites] AIDS. 1993 Nov;7 Suppl 2:S65-71 [7909227.001]
  • [Cites] N Engl J Med. 1994 Nov 3;331(18):1173-80 [7935654.001]
  • [Cites] Science. 1996 May 24;272(5265):1167-70 [8638160.001]
  • [Cites] Nat Rev Drug Discov. 2005 Nov;4(11):928-40 [16264436.001]
  • [Cites] RNA. 2006 Feb;12(2):256-62 [16373483.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):399-404 [16652046.001]
  • [Cites] J Infect Dis. 2006 Jul 1;194(1):1-5 [16741874.001]
  • [Cites] J Infect Dis. 2006 Jul 1;194(1):11-9 [16741877.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):254-9 [16837073.001]
  • [Cites] J Infect Dis. 2006 Sep 15;194 Suppl 1:S59-64 [16921474.001]
  • [Cites] J Med Virol. 2007 Feb;79(2):127-37 [17177310.001]
  • [Cites] Chem Biodivers. 2004 Jan;1(1):44-64 [17191775.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 Dec;22(12):1220-30 [17209763.001]
  • [Cites] J Virol Methods. 2007 Apr;141(1):49-57 [17184853.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2006;71:365-8 [17381318.001]
  • [Cites] N Engl J Med. 2007 Apr 26;356(17):1723-35 [17460226.001]
  • [Cites] Nat Biotechnol. 2007 Jun;25(6):669-74 [17546028.001]
  • [Cites] Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents [17630336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12422-7 [17640892.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1853-60 [17545188.001]
  • [Cites] Bioorg Med Chem. 2007 Dec 15;15(24):7576-80 [17900913.001]
  • [Cites] J Virol Methods. 2007 Dec;146(1-2):236-45 [17707519.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):257-67 [18097228.001]
  • [Cites] Drugs Today (Barc). 2007 Dec;43(12):865-77 [18174972.001]
  • [Cites] J Am Coll Cardiol. 2008 Jan 29;51(4):435-43 [18222353.001]
  • [Cites] PLoS Med. 2008 Jan 15;5(1):e16 [18198941.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;320:211-24 [18268846.001]
  • [Cites] Mol Ther. 2008 Mar;16(3):565-70 [18227841.001]
  • [Cites] Retrovirology. 2006;3:7 [16412247.001]
  • [Cites] N Engl J Med. 1988 Oct 6;319(14):889-96 [3166511.001]
  • [Cites] J Biol Chem. 1988 Oct 25;263(30):15354-7 [3262616.001]
  • [Cites] J Exp Med. 1988 Sep 1;168(3):1111-25 [2844951.001]
  • [Cites] J Acquir Immune Defic Syndr. 1988;1(2):125-30 [3145972.001]
  • [Cites] J Nucl Med. 1989 May;30(5):581-90 [2785582.001]
  • [Cites] Antimicrob Agents Chemother. 1989 Apr;33(4):479-83 [2658792.001]
  • [Cites] Science. 1989 Jul 28;245(4916):412-5 [2502840.001]
  • [Cites] Science. 1989 Dec 1;246(4934):1155-8 [2479983.001]
  • [Cites] Am J Med. 1990 May 21;88(5B):16S-19S [2159704.001]
  • [Cites] Semin Oncol. 1990 Jun;17(3):375-8 [2191441.001]
  • [Cites] Lancet. 1990 Sep 1;336(8714):526-9 [1975038.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):604-18 [1698042.001]
  • [Cites] Science. 1990 Sep 28;249(4976):1533-44 [1699273.001]
  • [Cites] Med Res Rev. 1990 Oct-Dec;10(4):419-39 [2243510.001]
  • [Cites] J Biol Chem. 2008 Aug 22;283(34):23353-63 [18519571.001]
  • [Cites] Cell. 2008 Aug 22;134(4):577-86 [18691745.001]
  • [Cites] N Engl J Med. 2008 Oct 2;359(14):1509-11 [18832250.001]
  • [Cites] Nat Biotechnol. 2008 Oct;26(10):1187-92 [18806783.001]
  • [Cites] Clin Ther. 2008 Oct;30(10):1747-65 [19014832.001]
  • [Cites] Antiviral Res. 2008 Dec;80(3):251-65 [18789977.001]
  • [Cites] Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):238-44 [19075633.001]
  • [Cites] AIDS. 2009 Jan 14;23(2):213-21 [19098491.001]
  • [Cites] Lancet. 2009 Jan 3;373(9657):48-57 [19038438.001]
  • [Cites] Clin Infect Dis. 2009 Mar 15;48(6):806-15 [19193111.001]
  • [Cites] Ann Intern Med. 2009 Mar 3;150(5):301-13 [19258558.001]
  • [Cites] Science. 2009 Mar 6;323(5919):1304-7 [19265012.001]
  • [Cites] Cell Host Microbe. 2009 Mar 19;5(3):285-97 [19286137.001]
  • [Cites] Antiviral Res. 2009 Apr;82(1):22-8 [19189851.001]
  • [Cites] Science. 2000 Jan 28;287(5453):607-14 [10649986.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):270-4 [10969352.001]
  • [Cites] BMJ. 2002 Jan 26;324(7331):232-4 [11809650.001]
  • [Cites] Pediatrics. 2002 Feb;109(2):E25 [11826235.001]
  • [Cites] Emerg Infect Dis. 2002 May;8(5):451-7 [11996677.001]
  • [Cites] AIDS. 1997 Jan;11(1):59-66 [9110076.001]
  • [Cites] Pharm World Sci. 1997 Aug;19(4):159-75 [9297727.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1302-7 [9809555.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):653-4 [15522650.001]
  • [Cites] Lancet. 2005 Aug 13-19;366(9485):549-55 [16099290.001]
  • [Cites] N Engl J Med. 2009 Apr 30;360(18):1808-10 [19403900.001]
  • [Cites] Int J Dev Biol. 2009;53(2-3):245-57 [19412884.001]
  • [Cites] Nucleic Acids Res. 2009 May;37(9):2984-95 [19304753.001]
  • [Cites] Retrovirology. 2009;6:40 [19409074.001]
  • [Cites] EMBO J. 2009 Jun 17;28(12):1708-19 [19461583.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] EMBO Rep. 2002 Sep;3(9):806-12 [12223456.001]
  • [Cites] N Engl J Med. 2003 Dec 11;349(24):2283-5 [14668451.001]
  • [Cites] Antivir Ther. 2004 Feb;9(1):3-12 [15040531.001]
  • [Cites] Lancet. 2004 Mar 20;363(9413):932-7 [15043960.001]
  • [Cites] Circulation. 2004 Apr 6;109(13):1603-8 [15023877.001]
  • [Cites] DNA Cell Biol. 2004 Apr;23(4):191-2 [15142376.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2711-7 [15184457.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):211-7 [15311210.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Oct;30(5):478-90 [15488024.001]
  • [Cites] Ann Intern Med. 1970 Dec;73(6):881-95 [5525541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Dec;71(12):4980-5 [4531031.001]
  • [Cites] J Med Chem. 1978 Jan;21(1):109-12 [563460.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1981 Jul 3;30(25):305-8 [6789108.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] J Am Acad Dermatol. 1981 Oct;5(4):468-71 [7287964.001]
  • [Cites] Science. 1984 Oct 12;226(4671):172-4 [6091268.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 [2413459.001]
  • [Cites] Lancet. 1986 Mar 15;1(8481):575-80 [2869302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911-5 [3006077.001]
  • [Cites] Biochem Pharmacol. 1986 Jul 1;35(13):2065-8 [3015143.001]
  • (PMID = 20018391.001).
  • [ISSN] 1872-9096
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Grant] United States / NIH HHS / OD / Z99 OD999999-01
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Number-of-references] 153
  • [Other-IDs] NLM/ NIHMS153574; NLM/ PMC2815149
  •  go-up   go-down


15. Greene K, Banerjee SC: Disease-related stigma: comparing predictors of AIDS and cancer stigma. J Homosex; 2006;50(4):185-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-related stigma: comparing predictors of AIDS and cancer stigma.
  • This study explores the prevalence of AIDS and cancer stigma as influenced by attitude toward homosexuality, religiosity, authoritarianism, and androgyny.
  • This study used a quasi-experimental survey design (N = 485) to examine attitude toward people with AIDS and cancer, and interaction with people with AIDS and cancer.
  • Negative attitudes toward homosexuality, high religious intensity and ideology, high authoritarianism, and low expressive emerged as factors related to more negative attitudes toward people with AIDS and unwillingness to interact with people with AIDS.
  • Attitudes toward people with cancer were generally not related to the variables.
  • Findings explore how to campaign efforts to reduce existing negative attitudes toward AIDS and homosexuality, given that gay men with AIDS are especially stigmatized.


16. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH: The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood; 2010 Apr 15;115(15):3017-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
  • This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20(+) diffuse large B-cell lymphoma.
  • There were no treatment-related deaths or new opportunistic infections during treatment, and patients had sustained CD4 cell count recovery and HIV viral control after treatment.
  • Tumor histogenesis was the only characteristic associated with lymphoma-specific outcome with 95% of germinal center B-cell (GCB) versus 44% of non-GCB diffuse large B-cell lymphoma (DLBCL) progression-free at 5 years.


17. Shaheen SO, Newson RB, Rayman MP, Wong AP, Tumilty MK, Phillips JM, Potts JF, Kelly FJ, White PT, Burney PG: Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma. Thorax; 2007 Jun;62(6):483-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary outcome was asthma-related quality of life (QoL) score.
  • Selenium supplementation was not associated with any significant improvement in secondary outcomes compared with placebo.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2002 Jun;121(6):1824-32 [12065345.001]
  • [Cites] Thorax. 2005 Apr;60(4):282-7 [15790982.001]
  • [Cites] Eur Respir J. 2004 Mar;23(3):456-63 [15065839.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD003538 [15106206.001]
  • [Cites] Lancet. 2004 May 22;363(9422):1724-7 [15158637.001]
  • [Cites] Thorax. 2004 Aug;59(8):652-6 [15282383.001]
  • [Cites] Ann N Y Acad Sci. 1982;393:70-82 [6816123.001]
  • [Cites] Am J Clin Nutr. 1999 Nov;70(5):896-903 [10539752.001]
  • [Cites] Am J Epidemiol. 2000 May 15;151(10):975-81 [10853636.001]
  • [Cites] Lancet. 2000 Jul 15;356(9225):233-41 [10963212.001]
  • [Cites] Eur Respir J. 2000 Aug;16(2):226-35 [10968496.001]
  • [Cites] Eur Respir J. 2000 Nov;16(5):808-16 [11153576.001]
  • [Cites] Br J Nutr. 2001 Mar;85(3):375-85 [11299083.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1823-8 [11734430.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17871-6 [11897787.001]
  • [Cites] Clin Sci (Lond). 1989 Nov;77(5):495-500 [2582721.001]
  • [Cites] Thorax. 1990 Feb;45(2):95-9 [2315881.001]
  • [Cites] Free Radic Biol Med. 1990;9(3):235-43 [2272532.001]
  • [Cites] J Clin Epidemiol. 1992 May;45(5):461-72 [1588352.001]
  • [Cites] Allergy. 1993 Jan;48(1):30-6 [8457023.001]
  • [Cites] J Clin Epidemiol. 1993 Oct;46(10):1103-11 [8410095.001]
  • [Cites] Thorax. 1994 Feb;49(2):171-4 [8128408.001]
  • [Cites] N Z Med J. 1994 Oct 12;107(987):387-91 [7936475.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Nov;10(11):1451-61 [7888200.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36 [7663792.001]
  • [Cites] Am J Public Health. 1995 Dec;85(12):1673-7 [7503343.001]
  • [Cites] Clin Exp Allergy. 1996 Jul;26(7):838-47 [8842559.001]
  • [Cites] BMJ. 1997 Feb 8;314(7078):387-8 [9040368.001]
  • [Cites] Thorax. 1997 Feb;52(2):166-70 [9059479.001]
  • [Cites] Eur Respir J. 1997 Jun;10(6):1224-9 [9192920.001]
  • [Cites] N Engl J Med. 1997 Nov 13;337(20):1405-11 [9358137.001]
  • [Cites] Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1574-9 [10228129.001]
  • [Cites] J Allergy Clin Immunol. 2005 Jun;115(6):1109-17; quiz 1118 [15940119.001]
  • [Cites] Biol Psychiatry. 2006 Jan 15;59(2):147-54 [16181615.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):804-10 [16614127.001]
  • [Cites] Clin Exp Allergy. 2003 Oct;33(10):1355-9 [14519140.001]
  • [Cites] Thorax. 1999 Jun;54(6):493-500 [10335002.001]
  • [Cites] Lancet. 1999 Aug 7;354(9177):482-3 [10465176.001]
  • [Cites] Br J Nutr. 2004 Oct;92(4):557-73 [15522125.001]
  • [CommentIn] Thorax. 2007 Jun;62(6):466-8 [17536025.001]
  • (PMID = 17234657.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Asthmatic Agents; 0 / Antioxidants; 0 / Bronchodilator Agents; H6241UJ22B / Selenium
  • [Other-IDs] NLM/ PMC2117223
  •  go-up   go-down


18. Denny P, Hagen FK, Hardt M, Liao L, Yan W, Arellanno M, Bassilian S, Bedi GS, Boontheung P, Cociorva D, Delahunty CM, Denny T, Dunsmore J, Faull KF, Gilligan J, Gonzalez-Begne M, Halgand F, Hall SC, Han X, Henson B, Hewel J, Hu S, Jeffrey S, Jiang J, Loo JA, Ogorzalek Loo RR, Malamud D, Melvin JE, Miroshnychenko O, Navazesh M, Niles R, Park SK, Prakobphol A, Ramachandran P, Richert M, Robinson S, Sondej M, Souda P, Sullivan MA, Takashima J, Than S, Wang J, Whitelegge JP, Witkowska HE, Wolinsky L, Xie Y, Xu T, Yu W, Ytterberg J, Wong DT, Yates JR 3rd, Fisher SJ: The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res; 2008 May;7(5):1994-2006
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultimately, information derived from the work reported here and related published studies can be used to translate blood-based clinical laboratory tests into a format that utilizes saliva.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):1017-23 [15473691.001]
  • [Cites] Arch Oral Biol. 2004 Dec;49(12):951-62 [15485636.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1423-30 [15492834.001]
  • [Cites] J Dent Res. 1987 Feb;66 Spec No:623-7 [3497964.001]
  • [Cites] Obstet Gynecol. 1990 Apr;75(4):701-4 [2179784.001]
  • [Cites] Biol Chem Hoppe Seyler. 1991 May;372(5):325-9 [1714742.001]
  • [Cites] J Biol Chem. 1991 Sep 15;266(26):17358-68 [1894623.001]
  • [Cites] J Biol Chem. 1991 Sep 25;266(27):17972-7 [1655733.001]
  • [Cites] Mol Immunol. 1993 Feb;30(3):277-86 [8433706.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(3-4):251-9 [8373982.001]
  • [Cites] Ann N Y Acad Sci. 1993 Sep 20;694:11-6 [8215048.001]
  • [Cites] Crit Rev Oral Biol Med. 1995;6(2):161-75 [7548622.001]
  • [Cites] Acta Paediatr. 1996 Jul;85(7):814-7 [8819547.001]
  • [Cites] Clin Chem. 1999 Sep;45(9):1431-8 [10471645.001]
  • [Cites] J Neurosci Res. 1999 Oct 15;58(2):301-7 [10502286.001]
  • [Cites] Biochemistry. 2005 Feb 15;44(6):2216-24 [15697247.001]
  • [Cites] Proteomics. 2006 Dec;6(23):6326-53 [17083142.001]
  • [Cites] Laryngorhinootologie. 2006 Dec;85(12):903-8 [16612747.001]
  • [Cites] Genome Biol. 2006;7(9):R80 [16948836.001]
  • [Cites] Genome Biol. 2006;7(8):R72 [16901338.001]
  • [Cites] J Neurochem. 2007 Nov;103(3):849-59 [17666040.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3588-600 [17968930.001]
  • [Cites] Proteomics. 2008 Feb;8(3):435-45 [18186022.001]
  • [Cites] Am J Med Sci. 1999 Dec;318(6):380-91 [10616163.001]
  • [Cites] Oral Oncol. 2000 May;36(3):272-6 [10793330.001]
  • [Cites] J Dent Res. 2000 Apr;79(4):976-82 [10831101.001]
  • [Cites] J Pathol. 2000 Sep;192(1):52-7 [10951400.001]
  • [Cites] J Clin Periodontol. 2000 Nov;27(11):810-8 [11073323.001]
  • [Cites] Oral Microbiol Immunol. 2000 Feb;15(1):10-4 [11155158.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] J Prosthet Dent. 2001 Feb;85(2):162-9 [11208206.001]
  • [Cites] Anat Rec. 2001 Oct 1;264(2):121-45 [11590591.001]
  • [Cites] Nature. 2002 Jan 10;415(6868):141-7 [11805826.001]
  • [Cites] Bioinformatics. 2002 Jan;18(1):207-8 [11836235.001]
  • [Cites] Adv Dent Res. 2000 Dec;14:22-8 [11842920.001]
  • [Cites] J Can Dent Assoc. 2002 Mar;68(3):170-4 [11911813.001]
  • [Cites] Gerontology. 2002 Sep-Oct;48(5):282-8 [12169792.001]
  • [Cites] Arch Oral Biol. 2002 Sep;47(9):631-5 [12243966.001]
  • [Cites] Mol Biotechnol. 2002 Sep;22(1):51-86 [12353914.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):5300-8 [12444093.001]
  • [Cites] J Proteome Res. 2002 Jan-Feb;1(1):21-6 [12643522.001]
  • [Cites] J Proteome Res. 2003 Jan-Feb;2(1):43-50 [12643542.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Sep;14(9):957-70 [12954164.001]
  • [Cites] J Periodontal Res. 2003 Dec;38(6):583-90 [14632921.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1109-15 [15048992.001]
  • [Cites] Anal Chem. 2004 Jun 1;76(11):197A-203A [15190879.001]
  • [Cites] Mol Cell Proteomics. 2004 Jun;3(6):531-3 [15075378.001]
  • [Cites] Proteomics. 2004 Jul;4(7):1985-8 [15221759.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i49-54 [15262780.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1384-8 [15371956.001]
  • [Cites] Clin Physiol. 1996 Jul;16(4):433-48 [8842578.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 4;229(1):193-7 [8954105.001]
  • [Cites] Anal Chem. 1997 Feb 15;69(4):767-76 [9043199.001]
  • [Cites] J Clin Periodontol. 1997 Jan;24(1):72-7 [9049801.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jan;42(1):83-6 [9116322.001]
  • [Cites] J Dent Res. 1997 Nov;76(11):1782-6 [9372796.001]
  • [Cites] Oral Dis. 1997 May;3 Suppl 1:S64-9 [9456660.001]
  • [Cites] Dig Dis Sci. 1998 Jun;43(6):1211-8 [9635610.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5922-8 [9637505.001]
  • [Cites] Fertil Steril. 1999 May;71(5):863-8 [10231047.001]
  • [Cites] Biochemistry. 2005 Mar 1;44(8):2885-99 [15723531.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jan;5(1):93-100 [15723595.001]
  • [Cites] J Dent. 2005 Mar;33(3):223-33 [15725522.001]
  • [Cites] Nat Methods. 2004 Dec;1(3):195-202 [15789030.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):159-67 [15890249.001]
  • [Cites] Expert Rev Proteomics. 2005 Aug;2(4):521-39 [16097886.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3226-45 [16104056.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3246-61 [16104057.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):667-75 [16118637.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Sep;6(9):702-14 [16231421.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1826-30 [16103422.001]
  • [Cites] Anal Chem. 2006 Jan 15;78(2):493-500 [16408932.001]
  • [Cites] J Physiol Biochem. 2005 Sep;61(3):469-80 [16440601.001]
  • [Cites] Int J Prosthodont. 2006 Jan-Feb;19(1):43-52 [16479760.001]
  • [Cites] Int J Prosthodont. 2006 Jan-Feb;19(1):53-60 [16479761.001]
  • [Cites] Proteomics. 2006 Mar;6(5):1631-9 [16402355.001]
  • [Cites] Nat Biotechnol. 2006 Mar;24(3):333-8 [16525410.001]
  • [Cites] J Am Dent Assoc. 2006 Mar;137(3):313-21 [16570464.001]
  • [Cites] Cell. 2006 Apr 7;125(1):173-86 [16615898.001]
  • [Cites] Eur J Oral Sci. 2006 Apr;114(2):147-53 [16630307.001]
  • [Cites] J Anat. 2006 May;208(5):609-19 [16637884.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):935-48 [16439352.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):787-8 [16670253.001]
  • [Cites] Pediatr Dent. 2006 Mar-Apr;28(2):110-7; discussion 192-8 [16708785.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1469-78 [16739998.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] J Chem Ecol. 2006 Jun;32(6):1149-63 [16770710.001]
  • [Cites] Am J Hum Biol. 2006 Jul-Aug;18(4):540-55 [16788889.001]
  • [Cites] J Neurochem. 2006 Jul;98(2):364-71 [16805831.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Aug;11(5):E449-55 [16878065.001]
  • [Cites] BMC Cancer. 2006;6:211 [16916471.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1811-8 [16735302.001]
  • [Cites] Curr HIV/AIDS Rep. 2006 Nov;3(4):169-75 [17032576.001]
  • [Cites] Neuroscience. 2006 Dec13;143(3):689-701 [16997486.001]
  • [Cites] J Dent Res. 2006 Dec;85(12):1129-33 [17122167.001]
  • (PMID = 18361515.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / U01 DE016267; United States / NIDCR NIH HHS / DE / U01 DE016275-04; United States / NIDCR NIH HHS / DE / DE016275-04; United States / NIDCR NIH HHS / DE / U01 DE016275; United States / NIDCR NIH HHS / DE / U01 DE016267-04; United States / NIDCR NIH HHS / DE / U01 DE 016274; United States / NIDCR NIH HHS / DE / U01 DE016274; United States / NIDCR NIH HHS / DE / DE016274-04; United States / NIDCR NIH HHS / DE / U01 DE016274-04; United States / NIDCR NIH HHS / DE / DE016267-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Proteome; 0 / Salivary Proteins and Peptides
  • [Other-IDs] NLM/ NIHMS109830; NLM/ PMC2839126
  •  go-up   go-down


19. Minkoff H, Zhong Y, Strickler HD, Watts DH, Palefsky JM, Levine AM, D'Souza G, Howard AA, Plankey M, Massad LS, Burk R: The relationship between cocaine use and human papillomavirus infections in HIV-seropositive and HIV-seronegative women. Infect Dis Obstet Gynecol; 2008;2008:587082
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Animal data suggest that cocaine has an immunosuppressive effect, but no human studies have been conducted to assess the relation of cocaine use with human papillomavirus (HPV) infection, the viral cause of cervical cancer.
  • RESULTS: In multivariate logistic regression models, censoring women treated for cervical neoplasia, crack/cocaine use within the last six months was associated with prevalent detection of oncogenic HPV DNA (odds ratio [OR] = 1.30 (1.09-1.55)), and with oncogenic HPV-positive squamous intraepithelial lesions (SIL) (OR = 1.70 (1.27-2.27)), following adjustment for age, race, HIV-serostatus, and CD4+ T-cell count, the number of sexual partners in the past six months, and smoking.
  • In multivariate Cox models crack/cocaine use was also associated with a trend that approached significance in regard to incident detection of oncogenic HPV-positive SIL (HR = 1.51, 95% CI 0.99-2.30), and while the rate of oncogenic HPV clearance was not related to cocaine use, the clearance of any SIL was significantly lower in those with versus those without recent crack/cocaine use (HR = 0.57, 95% CI 0.34-0.97).
  • CONCLUSIONS: Cocaine use is associated with an increased risk of detection of both prevalent and incident oncogenic HPV infection, as well as an increased risk of HPV-positive SIL over time.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cocaine.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. COCAINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2007 Feb;320(2):507-15 [17068203.001]
  • [Cites] Epidemiology. 1998 Mar;9(2):117-25 [9504278.001]
  • [Cites] J Infect Dis. 2001 Sep 15;184(6):682-90 [11517428.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):544-56 [11549560.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Apr;305(1):290-7 [12649381.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 16;95(14):1062-71 [12865452.001]
  • [Cites] J Infect Dis. 2004 May 15;189(10):1821-8 [15122518.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1049-60 [3233245.001]
  • [Cites] Am J Obstet Gynecol. 1990 Aug;163(2):521-6 [2386137.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Nov;259(2):745-50 [1941622.001]
  • [Cites] Clin Immunol Immunopathol. 1994 Mar;70(3):245-50 [7508835.001]
  • [Cites] J Infect Dis. 1994 Feb;169(2):235-40 [8106758.001]
  • [Cites] Am J Obstet Gynecol. 1998 May;178(5):982-6 [9609571.001]
  • [Cites] J Neuroimmunol. 1998 Mar 15;83(1-2):133-8 [9610681.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] Am J Obstet Gynecol. 1999 Apr;180(4):824-36 [10203650.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):577-86 [15840880.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S262-8 [16229879.001]
  • [Cites] Int Immunopharmacol. 2006 Jun;6(6):1029-33 [16644490.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):651-6 [16652040.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Life Sci. 1994;54(9):PL147-51 [8114610.001]
  • [Cites] Int J Immunopharmacol. 1994 Apr;16(4):311-9 [8045671.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Oct 28;204(2):820-7 [7980548.001]
  • [Cites] J Clin Microbiol. 1996 May;34(5):1058-64 [8727875.001]
  • [Cites] J Infect Dis. 1996 Oct;174(4):679-89 [8843203.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • (PMID = 18437233.001).
  • [ISSN] 1098-0997
  • [Journal-full-title] Infectious diseases in obstetrics and gynecology
  • [ISO-abbreviation] Infect Dis Obstet Gynecol
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / UO1-HD-32632; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NIAID NIH HHS / AI / UO1-AI-34994; United States / NIAID NIH HHS / AI / UO1-AI-34989; United States / NCRR NIH HHS / RR / MO1-RR-00083; United States / NIAID NIH HHS / AI / U01 AI031834; United States / NIAID NIH HHS / AI / U01 AI035004; United States / NIAID NIH HHS / AI / U01 AI034989; United States / NCRR NIH HHS / RR / M01 RR000071; United States / NIAID NIH HHS / AI / UO1-AI-35004; United States / NIAID NIH HHS / AI / UO1-AI-34993; United States / NIAID NIH HHS / AI / U01 AI034994; United States / NCRR NIH HHS / RR / MO1-RR-00079; United States / NIAID NIH HHS / AI / UO1-AI-42590; United States / NCI NIH HHS / CA / CA85178-06; United States / NCI NIH HHS / CA / R01 CA085178; United States / NIAID NIH HHS / AI / U01 AI034993; United States / NIAID NIH HHS / AI / UO1-AI-31834; United States / NCRR NIH HHS / RR / M01 RR000083; United States / NCRR NIH HHS / RR / MO1-RR-00071; United States / NICHD NIH HHS / HD / U01 HD032632; United States / NIAID NIH HHS / AI / U01 AI042590
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Egypt
  • [Chemical-registry-number] I5Y540LHVR / Cocaine
  • [Other-IDs] NLM/ PMC2324195
  •  go-up   go-down


20. Luty-Frackiewicz A: The role of selenium in cancer and viral infection prevention. Int J Occup Med Environ Health; 2005;18(4):305-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of selenium in cancer and viral infection prevention.
  • Selenium has important health effects related to the immune response and cancer prevention, which are possibly not exclusively linked to their enzymatic functions.
  • Selenium appears to be a key nutrient in counteracting the development of virulence and inhibiting HIV progression to AIDS.
  • An elevated selenium intake may be associated with reduced cancer risk.

  • MedlinePlus Health Information. consumer health - Infectious Diseases.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Occup Med Environ Health. 2006;19(2):149-50 [17128813.001]
  • [RetractionIn] Int J Occup Med Environ Health. 2007;20(1):V [17708013.001]
  • (PMID = 16617846.001).
  • [ISSN] 1232-1087
  • [Journal-full-title] International journal of occupational medicine and environmental health
  • [ISO-abbreviation] Int J Occup Med Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Isotopes; H6241UJ22B / Selenium
  •  go-up   go-down


21. Baldwin JA, Johnson JL, Benally CC: Building partnerships between indigenous communities and universities: lessons learned in HIV/AIDS and substance abuse prevention research. Am J Public Health; 2009 Apr;99 Suppl 1:S77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Building partnerships between indigenous communities and universities: lessons learned in HIV/AIDS and substance abuse prevention research.
  • Many HIV/AIDS and substance abuse prevention studies in American Indian and Alaska Native communities have been directed by academic researchers with little community input.
  • We examined the challenges in conducting HIV/AIDS-related research in American Indian and Alaska Native communities and the benefits of changing the research paradigm to a community-based participatory model.
  • These steps can enhance the long-term capacity of the community to conduct HIV/AIDS and substance abuse prevention research.
  • [MeSH-major] Community Health Services / organization & administration. Cooperative Behavior. HIV Infections / prevention & control. Health Services Research / organization & administration. Population Groups / statistics & numerical data. Research Personnel / education. Substance-Related Disorders / prevention & control. Universities / statistics & numerical data

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Public Health Rep. 2002;117 Suppl 1:S104-17 [12435834.001]
  • [Cites] Am J Public Health. 2002 Mar;92(3):443-4 [11867327.001]
  • [Cites] Am Psychol. 1991 Sep;46(9):931-46 [1958012.001]
  • [Cites] J Consult Clin Psychol. 1996 Oct;64(5):856-60 [8916611.001]
  • [Cites] J Sch Health. 1996 Nov;66(9):322-7 [8959591.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 1998;8(2):56-78 [9842066.001]
  • [Cites] J Health Care Poor Underserved. 1998 May;9(2):117-25 [10073197.001]
  • [Cites] J Urban Health. 2005 Jun;82(2 Suppl 3):iii44-55 [15933330.001]
  • [Cites] Cancer Control. 2005 Nov;12 Suppl 2:70-6 [16327753.001]
  • [Cites] Am J Public Health. 2006 Sep;96(9):1623-8 [16873759.001]
  • [Cites] J Public Health Manag Pract. 2007 Jan;Suppl:S49-54 [17159467.001]
  • [Cites] Public Health Rep. 2007 May-Jun;122(3):382-92 [17518310.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 2007;14(1):24-43 [17602411.001]
  • [Cites] Suicide Life Threat Behav. 1999 Winter;29(4):332-46 [10636327.001]
  • [Cites] Am Indian Alsk Native Ment Health Res. 2000;9(1):1-16 [11279550.001]
  • [Cites] Am J Public Health. 2004 Jan;94(1):13-4 [14713686.001]
  • (PMID = 19246672.001).
  • [ISSN] 1541-0048
  • [Journal-full-title] American journal of public health
  • [ISO-abbreviation] Am J Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2724951
  •  go-up   go-down


22. Mundodi V, Kucknoor AS, Alderete JF: Antisense RNA decreases AP33 gene expression and cytoadherence by T. vaginalis. BMC Microbiol; 2007 Jul 03;7:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As expected, AS-transfectants had lower levels of adherence to VECs, which was related to reduction in surface expression of AP33.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Biotechnol. 2003 Oct;14(5):505-11 [14580580.001]
  • [Cites] Microb Pathog. 1998 Jan;24(1):1-16 [9466942.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(4):1099-108 [15306014.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Infect Immun. 1982 Aug;37(2):755-62 [6288571.001]
  • [Cites] Infect Immun. 1983 Mar;39(3):1041-7 [6601618.001]
  • [Cites] Infect Immun. 1985 Dec;50(3):701-8 [3877690.001]
  • [Cites] Infect Immun. 1988 Jan;56(1):28-33 [3257206.001]
  • [Cites] Infect Immun. 1989 Oct;57(10):2991-7 [2789190.001]
  • [Cites] J Exp Med. 1991 Aug 1;174(2):311-8 [1856625.001]
  • [Cites] J Adolesc Health. 1998 Mar;22(3):205-8 [9502007.001]
  • [Cites] Mol Microbiol. 1998 Apr;28(2):305-13 [9622355.001]
  • [Cites] Mol Biochem Parasitol. 1999 Jan 25;98(2):203-14 [10080389.001]
  • [Cites] Int J Parasitol. 1999 Feb;29(2):199-212 [10221623.001]
  • [Cites] Sex Transm Dis. 1999 Apr;26(4 Suppl):S2-7 [10227693.001]
  • [Cites] J Parasitol. 1957 Aug;43(4):488-90 [13463700.001]
  • [Cites] Cell Microbiol. 2005 Feb;7(2):245-58 [15659068.001]
  • [Cites] J Clin Microbiol. 2005 Feb;43(2):684-7 [15695664.001]
  • [Cites] BMC Mol Biol. 2005;6:5 [15748280.001]
  • [Cites] Infect Immun. 2005 May;73(5):2602-10 [15845462.001]
  • [Cites] Infect Immun. 2005 Oct;73(10):6472-8 [16177319.001]
  • [Cites] Eukaryot Cell. 2005 Nov;4(11):1951-8 [16278462.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):939-45 [16702374.001]
  • [Cites] Infect Immun. 2006 Oct;74(10):5773-9 [16988255.001]
  • [Cites] Microbiology. 1998 Nov;144 ( Pt 11):3011-8 [9846736.001]
  • [Cites] Acta Oncol. 2000;39(1):71-5 [10752657.001]
  • [Cites] Infect Immun. 2000 Sep;68(9):4907-12 [10948104.001]
  • [Cites] Nature. 2001 Aug 16;412(6848):701-5 [11507631.001]
  • [Cites] Emerg Infect Dis. 2001 Nov-Dec;7(6):927-32 [11747718.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):519-22 [11797180.001]
  • [Cites] AIDS Wkly. 1995 Sep 18;:15-6 [12320247.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5153-62 [11741916.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 30;121(1):153-7 [11985873.001]
  • [Cites] J Infect Dis. 2002 Nov 15;186(10):1381-9 [12404152.001]
  • [Cites] J Infect Dis. 2002 Dec 1;186(11):1631-8 [12447740.001]
  • [Cites] Mol Microbiol. 2003 Mar;47(5):1207-24 [12603729.001]
  • [Cites] Mol Microbiol. 1992 Apr;6(7):853-62 [1602965.001]
  • [Cites] J Gen Microbiol. 1993 Dec;139(12):2879-89 [8126416.001]
  • [Cites] Int J Epidemiol. 1994 Aug;23(4):682-90 [8002180.001]
  • [Cites] Annu Rev Microbiol. 1994;48:713-42 [7826024.001]
  • [Cites] Mol Microbiol. 1995 Jul;17(1):69-83 [7476210.001]
  • [Cites] Microb Pathog. 1996 Jun;20(6):335-49 [8831829.001]
  • [Cites] Sex Transm Dis. 1997 Jul;24(6):353-60 [9243743.001]
  • [Cites] Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10 [14982671.001]
  • (PMID = 17608941.001).
  • [ISSN] 1471-2180
  • [Journal-full-title] BMC microbiology
  • [ISO-abbreviation] BMC Microbiol.
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ AY752938/ AY752939/ AY752941/ AY752942/ AY803186/ AY803187/ AY803189/ AY803190/ AY803191/ AY803192
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI043940; United States / NIAID NIH HHS / AI / R21 AI043940; United States / NIAID NIH HHS / AI / AI43940
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AP33 protein, Trichomonas vaginalis; 0 / DNA, Protozoan; 0 / Membrane Proteins; 0 / Protozoan Proteins; 0 / RNA, Antisense; 0 / RNA, Messenger; 0 / RNA, Protozoan
  • [Other-IDs] NLM/ PMC1929106
  •  go-up   go-down


23. Frank O, Giehl M, Zheng C, Hehlmann R, Leib-Mösch C, Seifarth W: Human endogenous retrovirus expression profiles in samples from brains of patients with schizophrenia and bipolar disorders. J Virol; 2005 Sep;79(17):10890-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only a subgroup of the HML-2 family (HERV-K10) was significantly overrepresented in both bipolar-disorder- and schizophrenia-associated samples compared to healthy brains, suggesting a potential association with disease.
  • Our data suggest that HERV transcription in brains is weakly correlated with schizophrenia and related diseases but may be influenced by the individual genetic background, brain-infiltrating immune cells, or medical treatment.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2004 Jan;78(2):1050-4 [14694139.001]
  • [Cites] Int MS J. 2003 Apr;10(1):22-8 [12906767.001]
  • [Cites] Cancer Immun. 2004 Feb 11;4:2 [14871062.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e31 [14973327.001]
  • [Cites] Biotechniques. 2004 Apr;36(4):628-33 [15088381.001]
  • [Cites] J Virol. 2004 Jun;78(12):6449-58 [15163738.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:83A-88A [15319094.001]
  • [Cites] Virology. 2004 Sep 15;327(1):93-110 [15327901.001]
  • [Cites] Nat Neurosci. 2004 Oct;7(10):1088-95 [15452578.001]
  • [Cites] J Virol. 2004 Nov;78(22):12157-68 [15507602.001]
  • [Cites] J Virol Methods. 2003 Sep;112(1-2):79-91 [12951215.001]
  • [Cites] Virology. 2003 Aug 15;313(1):44-55 [12951020.001]
  • [Cites] J Virol. 2003 Oct;77(19):10414-22 [12970426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13013-8 [14557543.001]
  • [Cites] J Virol. 2003 Dec;77(24):13161-70 [14645573.001]
  • [Cites] Lancet Neurol. 2004 Nov;3(11):637 [15515236.001]
  • [Cites] Arch Geschwulstforsch. 1980;50(8):758-62 [7224819.001]
  • [Cites] J Virol. 1989 Jan;63(1):64-75 [2462064.001]
  • [Cites] Dev Biol Stand. 1992;76:153-64 [1335930.001]
  • [Cites] Dev Biol Stand. 1993;80:45-52 [8270115.001]
  • [Cites] Schizophr Bull. 1995;21(2):167-71 [7631163.001]
  • [Cites] J Virol. 1995 Oct;69(10):6408-16 [7545247.001]
  • [Cites] Am J Med Genet. 1996 Feb 16;67(1):19-24 [8678109.001]
  • [Cites] Immunol Rev. 1996 Aug;152:193-236 [8930674.001]
  • [Cites] Schizophr Res. 1997 May 3;25(1):63-70 [9176928.001]
  • [Cites] Schizophr Res. 1997 Nov 7;28(1):1-38 [9428062.001]
  • [Cites] Virology. 1998 Aug 1;247(2):127-36 [9705905.001]
  • [Cites] Schizophr Bull. 1998;24(3):321-4 [9718626.001]
  • [Cites] N Engl J Med. 1999 Feb 25;340(8):603-8 [10029644.001]
  • [Cites] Genomics. 2004 Dec;84(6):982-90 [15533715.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3543-9 [15308565.001]
  • [Cites] J Virol. 2005 Jan;79(1):341-52 [15596828.001]
  • [Cites] J Virol. 2005 Jan;79(2):876-83 [15613316.001]
  • [Cites] J Neuroimmunol. 2005 Mar;160(1-2):195-203 [15710473.001]
  • [Cites] Am J Psychiatry. 1999 Nov;156(11):1725-9 [10553735.001]
  • [Cites] Science. 2000 Jan 28;287(5453):607-14 [10649986.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):785-9 [10693809.001]
  • [Cites] J Virol. 2000 Apr;74(7):3321-9 [10708449.001]
  • [Cites] Brain Res Brain Res Rev. 2000 Mar;31(2-3):193-9 [10719148.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):721-9 [10826479.001]
  • [Cites] Schizophr Res. 2000 Aug 3;44(2):151-5 [10913747.001]
  • [Cites] Trends Genet. 2000 Sep;16(9):418-20 [10973072.001]
  • [Cites] Schizophr Res. 2000 Nov 30;46(1):17-23 [11099881.001]
  • [Cites] Neuron. 2000 Nov;28(2):325-34 [11144342.001]
  • [Cites] Virology. 2001 Jan 5;279(1):280-91 [11145909.001]
  • [Cites] J Neurovirol. 2000 Dec;6(6):492-7 [11175321.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:456-67 [11268373.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4634-9 [11296294.001]
  • [Cites] Hum Gene Ther. 2001 May 1;12(7):743-9 [11339891.001]
  • [Cites] Virology. 2001 Sep 1;287(2):321-32 [11531410.001]
  • [Cites] Ann Neurol. 2001 Oct;50(4):434-42 [11601494.001]
  • [Cites] Brain Behav Immun. 2001 Dec;15(4):401-10 [11782106.001]
  • [Cites] Am J Obstet Gynecol. 2002 Feb;186(2):210-3 [11854637.001]
  • [Cites] Virology. 2002 Apr 25;296(1):1-5 [12036312.001]
  • [Cites] J Virol. 2002 Jul;76(13):6442-52 [12050356.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):222-7 [12707852.001]
  • [Cites] Mol Psychiatry. 2004 Jan;9(1):12-3 [14571258.001]
  • (PMID = 16103141.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Envelope Proteins
  • [Other-IDs] NLM/ PMC1193590
  •  go-up   go-down


24. Uphold CR, Rane D, Reid K, Tomar SL: Mental health differences between rural and urban men living with HIV infection in various age groups. J Community Health; 2005 Oct;30(5):355-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the disproportionate increase in rural, Southern residents and older persons during the third era of the HIV/AIDS epidemic, no known study has examined whether older, rural men living with HIV infection face a double jeopardy and have poorer psychosocial profiles than other subgroups of men.
  • We investigated whether area of residence (rural, urban), age (young, middle-age, old), and the interaction of residence and age would be related to mental health factors by using two measurement methods to categorize rural and urban residence (US Census Bureau classification and The Office of Rural Health Policy's, Rural Urban Commuting Area Codes [RUCAs]).
  • Using two methods to categorize area of residence, we found that rural men as compared to urban men had similar levels of total stress, AIDS-related stress, social support, active coping and avoidance coping, but higher rates of risk for depression.
  • Rural men had higher levels of non-AIDS-related stress only when the US Census Bureau's categorization was used, which highlights the importance of carefully selecting and describing methods to categorize rural versus urban residence.


25. Mehta AS, Long RE, Comunale MA, Wang M, Rodemich L, Krakover J, Philip R, Marrero JA, Dwek RA, Block TM: Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol; 2008 Feb;82(3):1259-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis B and C viruses are major causative agents of liver fibrosis, cirrhosis, and liver cancer.
  • The reason for the alteration in the glycosylation of anti-Gal IgG is currently unclear but may be related to the natural history of the disease and may be useful in the noninvasive detection of fibrosis and cirrhosis.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antivir Ther. 2004 Dec;9(6):1013-26 [15651760.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1682-90 [10446868.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):381-9 [15750391.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Immunol Cell Biol. 2005 Dec;83(6):674-86 [16266320.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):3072-82 [16276416.001]
  • [Cites] J Proteome Res. 2006 Feb;5(2):308-15 [16457596.001]
  • [Cites] J Immunol. 2006 Aug 1;177(3):1737-45 [16849483.001]
  • [Cites] Science. 2006 Aug 4;313(5787):670-3 [16888140.001]
  • [Cites] J Hepatol. 2006 Nov;45(5):744-57 [16979776.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1957-67 [16760258.001]
  • [Cites] Annu Rev Immunol. 2007;25:21-50 [17029568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8433-7 [17485663.001]
  • [Cites] Hepatology. 2007 Sep;46(3):618-21 [17879361.001]
  • [Cites] Biotechnol Genet Eng Rev. 1999;16:1-21 [10819075.001]
  • [Cites] J Hepatol. 2001 Dec;35(6):749-55 [11738102.001]
  • [Cites] Hepatology. 2002 Dec;36(6):1349-54 [12447858.001]
  • [Cites] J Hepatol. 2003;39 Suppl 1:S111-5 [14708688.001]
  • [Cites] Proteomics. 2004 Mar;4(3):826-38 [14997503.001]
  • [Cites] J Viral Hepat. 2004 May;11(3):251-6 [15117327.001]
  • [Cites] Nat Med. 2004 Apr;10(4):429-34 [15152612.001]
  • [Cites] Biochem Biophys Res Commun. 1977 Nov 21;79(2):388-95 [412499.001]
  • [Cites] Liver. 1984 Jun;4(3):214-8 [6748875.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):452-7 [3927174.001]
  • [Cites] Lancet. 1988 Apr 30;1(8592):966-9 [2896829.001]
  • [Cites] Br J Rheumatol. 1988;27 Suppl 2:162-9 [3135870.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):1005-8 [2375310.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2485-93 [7691263.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Anal Biochem. 1996 Sep 5;240(2):210-26 [8811911.001]
  • [Cites] Curr Opin Biotechnol. 1997 Aug;8(4):488-97 [9265730.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S [9305658.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):34S-38S [9305661.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S [9305666.001]
  • [Cites] Autoimmunity. 1998;28(1):25-30 [9754811.001]
  • [Cites] Eur J Biochem. 1998 Dec 1;258(2):623-56 [9874230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):779-84 [15642945.001]
  • (PMID = 18045939.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120206; United States / NCI NIH HHS / CA / U01 CA084951; United States / NCI NIH HHS / CA / R01 CA120206-01; United States / NCI NIH HHS / CA / UO1 CA084951-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Lectins; 0 / Trisaccharides; 0 / alpha-galactosyl epitope; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ PMC2224448
  •  go-up   go-down


26. Berretta M, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, Cacopardo B, Nunnari G, Montesarchio V, Izzi I, Lanzafame M, Nasti G, Basile F, Berretta S, Fisichella R, Schiantarelli C C, Garlassi E, Ridolfo A, Guella L, Tirelli U: Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res; 2010 Apr;8(3):218-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection.
  • BACKGROUND: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC.
  • PATIENTS AND METHODS: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT).
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / adverse effects. Antiretroviral Therapy, Highly Active / methods. Drug Therapy / methods. Drug-Related Side Effects and Adverse Reactions. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Italy. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use. Treatment Outcome


27. Strine TW, Chapman DP, Balluz L, Mokdad AH: Health-related quality of life and health behaviors by social and emotional support. Their relevance to psychiatry and medicine. Soc Psychiatry Psychiatr Epidemiol; 2008 Feb;43(2):151-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and health behaviors by social and emotional support. Their relevance to psychiatry and medicine.
  • BACKGROUND: Social and emotional support is an important construct, which has been associated with a reduced risk of mental illness, physical illness, and mortality.
  • In order to better address this issue, we examined health-related quality of life (HRQOL) and health behaviors by level of social and emotional support in community-dwelling adults in the United States and its territories.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Qual Life Outcomes. 2003 Sep 02;1:37 [14498988.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2006 May;61(3):S147-52 [16670192.001]
  • [Cites] Acta Psychiatr Scand Suppl. 2006;(429):46-50 [16445482.001]
  • [Cites] Psychol Sci. 2003 Jul;14(4):320-7 [12807404.001]
  • [Cites] J Psychol. 2006 May;140(3):229-46 [16916076.001]
  • [Cites] J Health Soc Behav. 1994 Sep;35(3):193-212 [7983334.001]
  • [Cites] J Adv Nurs. 1997 Jan;25(1):95-100 [9004016.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 May 6;54(17):433-7 [15889012.001]
  • [Cites] J Behav Med. 2006 Oct;29(5):449-60 [16958004.001]
  • [Cites] J Ethn Subst Abuse. 2006;5(3):49-60 [17135167.001]
  • [Cites] Soc Sci Med. 1990;30(5):635-7 [2309140.001]
  • [Cites] Ann Fam Med. 2004 Mar-Apr;2(2):170-4 [15083859.001]
  • [Cites] Ann Epidemiol. 1996 Sep;6(5):442-51 [8915476.001]
  • [Cites] Cancer Nurs. 2006 Mar-Apr;29(2):120-31; quiz 132-3 [16565621.001]
  • [Cites] Patient Couns Health Educ. 1982;4(2):65-79 [10258419.001]
  • [Cites] Tob Control. 2002 Dec;11(4):361-7 [12432162.001]
  • [Cites] J Health Soc Behav. 1979 Jun;20(2):108-19 [479524.001]
  • [Cites] J Behav Med. 1993 Apr;16(2):199-218 [8315646.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2000 Nov;55(6):S323-33 [11078109.001]
  • [Cites] J Psychosom Res. 1996 Aug;41(2):171-80 [8887830.001]
  • [Cites] Soc Sci Med. 2004 Apr;58(7):1353-66 [14759681.001]
  • [Cites] AIDS Patient Care STDS. 2001 Apr;15(4):211-5 [11359663.001]
  • [Cites] J Epidemiol Community Health. 2003 May;57(5):339-43 [12700216.001]
  • [Cites] J Pers Soc Psychol. 1984 May;46(5):1097-1108 [6737206.001]
  • [Cites] Am J Health Promot. 2000 Jul-Aug;14(6):362-70 [11067571.001]
  • [Cites] Soc Sci Med. 2001 Jan;52(2):315-22 [11144787.001]
  • [Cites] Health Rep. 2003 May;14(3):21-34 [12816013.001]
  • [Cites] Nurs Res. 1986 Nov-Dec;35(6):334-8 [3640349.001]
  • [Cites] AIDS Patient Care STDS. 2004 Oct;18(10):594-603 [15630787.001]
  • [Cites] Depress Anxiety. 2007;24(8):563-70 [17133441.001]
  • [Cites] Sleep Med. 2005 Jan;6(1):23-7 [15680291.001]
  • [Cites] Acta Psychiatr Scand. 2005 Feb;111(2):125-32 [15667431.001]
  • [Cites] AIDS Care. 2000 Oct;12(5):673-84 [11218552.001]
  • [Cites] Diabetes Care. 1984 Nov-Dec;7(6):566-74 [6510181.001]
  • [Cites] Psychiatr Serv. 2004 Dec;55(12):1408-13 [15572569.001]
  • [Cites] Ann Behav Med. 2006 Feb;31(1):36-44 [16472037.001]
  • [Cites] J Holist Nurs. 1995 Jun;13(2):174-98 [7745242.001]
  • [Cites] Cancer Nurs. 2001 Jun;24(3):212-9 [11409065.001]
  • [Cites] Qual Life Res. 2003;12 Suppl 1:25-31 [12803308.001]
  • [Cites] Health Psychol. 2004 Mar;23(2):207-18 [15008666.001]
  • [Cites] J Adv Nurs. 1993 Feb;18(2):203-10 [8436711.001]
  • [Cites] Health Qual Life Outcomes. 2006 Sep 24;4:66 [16995955.001]
  • [Cites] J Consult Clin Psychol. 1986 Aug;54(4):447-53 [3745596.001]
  • [Cites] Qual Life Res. 1998 Dec;7(8):735-50 [10097622.001]
  • [Cites] Health Psychol. 1988;7(3):269-97 [3289916.001]
  • [Cites] J Am Coll Health. 2005 May-Jun;53(6):276-84 [15900991.001]
  • [Cites] Psychiatry Clin Neurosci. 2006 Oct;60(5):563-9 [16958939.001]
  • [Cites] Cancer Nurs. 1996 Jun;19(3):162-9 [8674024.001]
  • [Cites] Addict Behav. 2005 Jul;30(6):1225-9 [15925130.001]
  • [Cites] Am J Epidemiol. 1982 May;115(5):684-94 [7081200.001]
  • [Cites] Int J Behav Med. 1998;5(2):166-82 [16250711.001]
  • [Cites] J Behav Med. 2006 Aug;29(4):377-87 [16758315.001]
  • [Cites] J Consult Clin Psychol. 1999 Feb;67(1):132-8 [10028217.001]
  • [Cites] Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S179-86 [16052189.001]
  • [Cites] MMWR Recomm Rep. 2003 May 23;52(RR-9):1-12 [12817947.001]
  • [Cites] Am J Prev Med. 2005 Feb;28(2):182-7 [15710274.001]
  • [Cites] Psychosom Med. 1995 May-Jun;57(3):245-54 [7652125.001]
  • [Cites] Soc Sci Med. 1999 Sep;49(6):781-9 [10459889.001]
  • [Cites] J Health Soc Behav. 1986 Sep;27(3):250-64 [3772062.001]
  • [Cites] Am J Epidemiol. 1983 May;117(5):521-37 [6342368.001]
  • [Cites] Prev Chronic Dis. 2005 Jan;2(1):A15 [15670468.001]
  • (PMID = 17962895.001).
  • [ISSN] 0933-7954
  • [Journal-full-title] Social psychiatry and psychiatric epidemiology
  • [ISO-abbreviation] Soc Psychiatry Psychiatr Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Salit IE, Tinmouth J, Chong S, Raboud J, Diong C, Su D, Sano M, Lytwyn A, Chapman W, Mahony J: Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev; 2009 Jul;18(7):1986-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology.
  • BACKGROUND: HIV-positive men with a history of anal-receptive intercourse are at risk for anal cancer.
  • HPV types 16, 18, 31, 52, 59, and 68 were associated with high-grade histology.
  • HPV 16 viral load was also associated with AIN 2/3 histology.
  • In the multivariable logistic regression model, HPV genotypes 16 [odds ratio, 2.58; 95% confidence interval (95% CI), 1.31-5.08; P = 0.006] and 31 (odds ratio, 4.74; 95% CI, 2.00-11.22; P = 0.0004), baseline CD4 count < 400 cells/mm(3) (odds ratio, 2.96; 95% CI, 1.46-5.99; P = 0.0025), and Acquired Immunodeficiency Syndrome (AIDS)-defining illness (odds ratio, 2.42; 95% CI, 1.22-4.82; P = 0.01) were associated with high-grade histology after adjusting for age.
  • CONCLUSIONS: The presence of high-grade anal pathology (AIN 2/3) in HIV-positive men was associated with multiple HPV genotypes, HPV genotypes 16 and 31, and HPV 16 viral load.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / virology. DNA, Viral / analysis. Genotype. Homosexuality, Male. Humans. Male. Papillomavirus Infections / complications. Papillomavirus Infections / epidemiology. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Risk Factors. Viral Load

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567510.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins
  •  go-up   go-down


29. Vidrine DJ: Cigarette smoking and HIV/AIDS: health implications, smoker characteristics and cessation strategies. AIDS Educ Prev; 2009 Jun;21(3 Suppl):3-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking and HIV/AIDS: health implications, smoker characteristics and cessation strategies.
  • Although mortality attributable to AIDS-related diseases has decreased dramatically in the current era of combination antiretroviral therapy, the proportion of deaths attributable to other diseases (e.g., cardiovascular, pulmonary, and cancer) in this population has markedly increased.
  • Thus, efforts to reduce morbidity and mortality attributable to these non-AIDS-defining diseases represent an important public health priority.
  • Existing evidence indicates that smoking prevalence is significantly elevated among persons living with HIV/AIDS.
  • In addition, smoking is associated with numerous HIV-related adverse outcomes.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537950.001).
  • [ISSN] 1943-2755
  • [Journal-full-title] AIDS education and prevention : official publication of the International Society for AIDS Education
  • [ISO-abbreviation] AIDS Educ Prev
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA097893; United States / NCI NIH HHS / CA / R01CA097893
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


30. Xu T, Wu Z, Yan Z, Rou K, Duan S: Measuring health-related quality of life in children living in HIV/AIDS-affected families in rural areas in Yunnan, China: Preliminary reliability and validity of the Chinese version of PedsQL 4.0 generic core scales. J Acquir Immune Defic Syndr; 2010 Feb;53 Suppl 1:S111-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measuring health-related quality of life in children living in HIV/AIDS-affected families in rural areas in Yunnan, China: Preliminary reliability and validity of the Chinese version of PedsQL 4.0 generic core scales.
  • OBJECTIVES: To investigate the preliminary reliability and validity of the Chinese Mandarin version of the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales in a sample of general children and children living in HIV/AIDS-affected families.
  • METHODS: The PedsQL 4.0 was administered to 116 children aged 8-18 years from HIV/AIDS-affected families and 115 of their caregivers.
  • On average, children living in HIV/AIDS-affected families scored significantly lower than the control group.
  • The health-related quality of life for children living in HIV families is lower than children from ordinary families.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Technol Assess. 2001;5(4):1-157 [11262421.001]
  • [Cites] J Child Psychol Psychiatry. 2001 Jul;42(5):661-7 [11464970.001]
  • [Cites] Med Care. 2001 Aug;39(8):800-12 [11468499.001]
  • [Cites] Soc Sci Med. 2003 Jul;57(2):301-11 [12765710.001]
  • [Cites] Ambul Pediatr. 2003 Nov-Dec;3(6):329-41 [14616041.001]
  • [Cites] JAMA. 1996 May 1;275(17):1329-34 [8614118.001]
  • [Cites] AIDS Care. 2006 Oct;18(7):647-55 [16971271.001]
  • [Cites] Soc Sci Med. 2005 Aug;61(3):555-64 [15899315.001]
  • [Cites] Am J Orthopsychiatry. 2005 Oct;75(4):658-75 [16262522.001]
  • [Cites] Qual Life Res. 2006 Mar;15(2):203-15 [16468077.001]
  • [Cites] Cancer. 2006 May 15;106(10):2267-74 [16604563.001]
  • [Cites] Health Qual Life Outcomes. 2006;4:58 [16942613.001]
  • [Cites] Med Care. 1999 Feb;37(2):126-39 [10024117.001]
  • (PMID = 20104101.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U2RTW006917; United States / FIC NIH HHS / TW / U2R TW006917; United States / NCBDD CDC HHS / DD / U10 DD000064; United States / FIC NIH HHS / TW / U2R TW006918-06; United States / FIC NIH HHS / TW / TW006918-06; United States / FIC NIH HHS / TW / U2R TW006918; United States / PHS HHS / / U2RTW006918
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS166995; NLM/ PMC2818829
  •  go-up   go-down


31. Edwards TA, Thompson HS, Kwate NO, Brown K, McGovern MM, Forman A, Kapil-Pair N, Jandorf L, Bovbjerg DH, Valdimarsdottir HB: Association between temporal orientation and attitudes about BRCA1/2 testing among women of African descent with family histories of breast cancer. Patient Educ Couns; 2008 Aug;72(2):276-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between temporal orientation and attitudes about BRCA1/2 testing among women of African descent with family histories of breast cancer.
  • OBJECTIVE: Previous studies have identified specific attitudes (pros and cons) about BRCA testing held by women of African descent that are associated with decisions to participate in testing.
  • The current study explored the relationship between temporal orientation and pros and cons of BRCA testing among 140 women of African descent with a family history suggestive of a genetic mutation predisposing to breast cancer.
  • RESULTS: Multivariate analyses indicated that future orientation was positively associated with perceived pros of testing.
  • Additional analyses revealed significant associations between temporal orientation and specific item subsets related to the negative and positive impact of testing on family and personal control over one's health.
  • CONCLUSION: These results support an association between temporal orientation and attitudes about BRCA testing among women of African descent with family histories of breast cancer.
  • PRACTICE IMPLICATIONS: Findings support exploration of temporal orientation in future research on BRCA testing decisions among women of African descent and this construct's importance in developing decision aids and tailoring genetic counseling.


32. Sela M: Immunomodulatory vaccines against autoimmune diseases. Rejuvenation Res; 2006;9(1):126-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts to develop vaccines against such diseases as cancer, AIDS, hepatitis, tuberculosis, Alzheimer disease, and mad cow disease have not yet reached the stage where they can be successfully used on a daily basis.
  • The drug or therapeutic vaccine against the exacerbating-remitting type of multiple sclerosis is a copolymer of four amino acid residues, denoted Copaxone, which are related to myelin basic protein.
  • Altered peptide ligand, composed of the randomly arranged two single amino acid analogs inhibits in vitro and in vivo MG-associated autoimmune responses.
  • The active suppression is mediated by the CD4+ CD25+ immunoregulatory cells and is associated with the downregulation of Th1-type cytokines and upregulation of the secretion of IL-10 and the immunosuppressive cytokine transforming growth factor beta.

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608409.001).
  • [ISSN] 1549-1684
  • [Journal-full-title] Rejuvenation research
  • [ISO-abbreviation] Rejuvenation Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Peptides; 0 / Receptors, Cholinergic; 0 / Vaccines; 5M691HL4BO / Glatiramer Acetate
  • [Number-of-references] 47
  •  go-up   go-down


33. Sarker D, Workman P: Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res; 2007;96:213-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic biomarkers for molecular cancer therapeutics.
  • Rational and efficient development of new molecular cancer therapeutics requires discovery, validation, and implementation of informative biomarkers.
  • Applying biomarkers in early clinical trials helps identify the most appropriate patients; provides proof of concept for target modulation; helps test the underlying hypothesis; informs the rational selection of dose and schedule; aids decision making, including key go/no go questions; and may explain or predict clinical outcomes.
  • Despite many successes such as trastuzumab and imatinib, exemplifying the value of targeting specific cancer defects, only 5% of oncology drugs that enter the clinic make it to marketing approval.
  • Use of biomarkers should reduce this high level of attrition and bring forward key decisions (e.g., "fail fast"), thereby reducing the spiraling costs of drug development and increasing the likelihood of getting innovative and active drugs to cancer patients.
  • We also discuss related clinical trial design issues.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17161682.001).
  • [ISSN] 0065-230X
  • [Journal-full-title] Advances in cancer research
  • [ISO-abbreviation] Adv. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 223
  •  go-up   go-down


34. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood; 2006 Dec 1;108(12):3786-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.
  • In persons with HIV/AIDS (PWHAs), Hodgkin lymphoma (HL) risk is increased.
  • We linked nationwide HIV/AIDS and cancer registry data from 1980 through 2002.
  • Immunity was assessed by CD4 T-lymphocyte counts at AIDS onset.
  • Annual HL incidence rates were calculated for 4 through 27 months after AIDS onset.
  • During 477 368 person years (py's) of follow-up in 317 428 persons with AIDS (PWAs), 173 HL cases occurred (36.2 per 10(5) py's).
  • We conclude that HL incidence is lower with severe immunosuppression than with moderate immunosuppression, and HAART-related improvements in CD4 counts likely explain the increasing HL incidence in PWHAS observed since 1996.


35. Katerndahl DA: Impact of spiritual symptoms and their interactions on health services and life satisfaction. Ann Fam Med; 2008 Sep-Oct;6(5):412-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Spiritual symptoms (alone or in interaction) were associated with 7 of the 10 outcomes and were particularly important to extreme use of health care services and life satisfaction.
  • Among best-fit models, spiritual symptoms alone were significantly associated with any mental health use (beta =0.694, P < or = .05), fair-poor health status (beta =0.837, P < or = .05), and life lacking meaning (beta =1.214, P < or = .001).
  • Extreme utilization outcomes were related to the number of chronic problems, as well as to the social-spiritual interaction.
  • Satisfaction outcomes were associated with physical and spiritual symptoms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychooncology. 1999 Sep-Oct;8(5):417-28 [10559801.001]
  • [Cites] Ann Fam Med. 2004 Nov-Dec;2(6):576-82 [15576544.001]
  • [Cites] Br J Gen Pract. 2005 Feb;55(511):154-5 [15720949.001]
  • [Cites] Psychiatr Serv. 2005 Jun;56(6):678-84 [15939943.001]
  • [Cites] J Stud Alcohol. 2005 Mar;66(2):295-304 [15957682.001]
  • [Cites] Ann Fam Med. 2005 Jul-Aug;3(4):324-30 [16046565.001]
  • [Cites] J Clin Gastroenterol. 2005 Sep;39(8):665-9 [16082273.001]
  • [Cites] AIDS Patient Care STDS. 2005 Aug;19(8):473-85 [16124841.001]
  • [Cites] Aust N Z J Psychiatry. 2005 Sep;39(9):795-9 [16168037.001]
  • [Cites] Rehabil Nurs. 2006 Jul-Aug;31(4):149-54 [16789672.001]
  • [Cites] J Psychosom Res. 2006 Aug;61(2):229-36 [16880026.001]
  • [Cites] Appl Psychophysiol Biofeedback. 2006 Jun;31(2):155-65 [16868844.001]
  • [Cites] J Am Geriatr Soc. 2006 Oct;54(10):1516-23 [17038068.001]
  • [Cites] South Med J. 2006 Dec;99(12):1340-4 [17240561.001]
  • [Cites] Int J Psychiatry Med. 2007;37(4):393-414 [18441628.001]
  • [Cites] Int J Behav Med. 2004;11(4):197-202 [15657019.001]
  • [Cites] Health Serv Res. 2000 Feb;34(6):1273-302 [10654830.001]
  • [Cites] Arch Pediatr Adolesc Med. 2000 Apr;154(4):361-5 [10768673.001]
  • [Cites] Arch Psychiatr Nurs. 2000 Aug;14(4):173-82 [10969637.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2002 May;37(5):212-9 [12107712.001]
  • [Cites] Biol Psychiatry. 2003 Aug 1;54(3):399-409 [12893114.001]
  • [Cites] Soc Sci Med. 2004 Jun;58(11):2145-8 [15047073.001]
  • [Cites] Ann Fam Med. 2004 Jan-Feb;2(1):49-53 [15053283.001]
  • [Cites] Int J Psychiatry Med. 2003;33(4):377-89 [15152787.001]
  • [Cites] Arch Intern Med. 2004 Jul 26;164(14):1579-85 [15277293.001]
  • [Cites] Science. 1977 Apr 8;196(4286):129-36 [847460.001]
  • [Cites] Am J Psychiatry. 1980 May;137(5):535-44 [7369396.001]
  • [Cites] Soc Sci Med Med Psychol Med Sociol. 1980 Dec;14A(6):683-5 [7209642.001]
  • [Cites] Soc Sci Med. 1987;24(7):589-600 [3589753.001]
  • [Cites] Arch Gen Psychiatry. 1987 Aug;44(8):687-94 [3498452.001]
  • [Cites] Psychosomatics. 1987 Nov;28(11):582-4, 586 [3324156.001]
  • [Cites] Soc Sci Med. 1988;27(12):1369-79 [3070763.001]
  • [Cites] J Fam Pract. 1989 Jul;29(1):59-63; discussion 63-4 [2738550.001]
  • [Cites] J Fam Pract. 1990 Mar;30(3):271-2 [2307941.001]
  • [Cites] J Fam Pract. 1990 Mar;30(3):273-80 [2134156.001]
  • [Cites] Soc Sci Med. 1990;31(12):1347-63 [2126895.001]
  • [Cites] Int J Soc Psychiatry. 1991 Spring;37(1):57-63 [2045243.001]
  • [Cites] JAMA. 1992 Mar 25;267(12):1617-23 [1542171.001]
  • [Cites] Cancer Nurs. 1992 Feb;15(1):1-8 [1544127.001]
  • [Cites] Med Care. 1992 May;30(5):400-11 [1583918.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] J Stud Alcohol. 1993 May;54(3):297-301 [8487537.001]
  • [Cites] JAMA. 1995 Jan 4;273(1):59-65 [7996652.001]
  • [Cites] J Health Soc Behav. 1995 Mar;36(1):1-10 [7738325.001]
  • [Cites] Int J Cardiol. 1997 Apr 18;59(2):161-6 [9158169.001]
  • [Cites] Psychiatr Serv. 1997 Aug;48(8):1027-32 [9255834.001]
  • [Cites] Ann Emerg Med. 1997 Sep;30(3):286-91 [9287889.001]
  • [Cites] South Med J. 1998 Oct;91(10):925-32 [9786287.001]
  • [Cites] J Fam Pract. 1999 May;48(5):372-7 [10334614.001]
  • [CommentIn] Ann Fam Med. 2008 Sep-Oct;6(5):388-9 [18779541.001]
  • (PMID = 18779545.001).
  • [ISSN] 1544-1717
  • [Journal-full-title] Annals of family medicine
  • [ISO-abbreviation] Ann Fam Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2532769
  •  go-up   go-down


36. Lillo FB, Uberti-Foppa C: Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women. J Antimicrob Chemother; 2006 May;57(5):810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laboratory markers of human papillomavirus infection have been recognized as relevant tools in programmes designed to reduce the burden of cervical cancer.
  • Among the possible virus-related parameters proposed as relevant markers (viral persistence, load, expression, genomic integration capacity) we here analyse the informative value of human papillomavirus viral load measurement as a possible risk marker in this particular clinical setting.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556637.001).
  • [ISSN] 0305-7453
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


37. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D: The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer; 2007;120 Suppl 12:1-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NHL accounts for approximately 3.4% of cancer deaths in the US.
  • Although some of the observed patterns in NHL have been related to HIV/AIDS, these conditions cannot fully explain the magnitude of the changes; neither do changes in classification systems nor improved diagnostic capabilities.
  • Family history of NHL or other hematolympho-proliferative cancers and personal history of several autoimmune disorders are associated with increased risk of NHL, but are not likely to account for a large proportion of cases.
  • HIV and other infectious agents, such as human herpesvirus 8 and Epstein-Barr, appear to be associated with differing types of NHL, such as some B-cell lymphomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405121.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 684
  •  go-up   go-down


38. Grkovic S, Nikolic R, Dordevic M, Stojanov L: Urinary catecholamine metabolites: Capillary gas chromatography method and experience with 12 cases of neuroblastoma. Indian J Clin Biochem; 2005 Jul;20(2):178-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We propose a rapid, simple metodology for routine analysis of human urine to detect vanillylmandelic and homovanillic acid related to neuroblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):538-43 [1399133.001]
  • [Cites] J Clin Pathol. 1991 Apr;44(4):269-75 [2030143.001]
  • [Cites] J Chromatogr. 1988 Nov 18;432:273-7 [3220894.001]
  • [Cites] Clin Chem. 1983 May;29(5):828-31 [6839460.001]
  • [Cites] Clin Chem. 1997 Oct;43(10):1999-2001 [9342031.001]
  • [Cites] JAMA. 1963 Mar 9;183:836-40 [14000837.001]
  • [Cites] Ann Clin Biochem. 2004 Jan;41(Pt 1):17-38 [14713382.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2186-95 [7697611.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):745-54 [9328197.001]
  • (PMID = 23105556.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453848
  • [Keywords] NOTNLM ; Capillary gas chromatography / Homovanillic acid / diagnostic aids / neuroblastoma / vanillylmandelic acid
  •  go-up   go-down


39. UyBico SJ, Pavel S, Gross CP: Recruiting vulnerable populations into research: a systematic review of recruitment interventions. J Gen Intern Med; 2007 Jun;22(6):852-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DATA SOURCES: Studies were identified by searching MEDLINE, the Web of Science database, personal sources, hand searching of related journals, and article references.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gerontologist. 2003 Feb;43(1):36-44 [12604744.001]
  • [Cites] Gerontologist. 2003 Feb;43(1):52-61 [12604746.001]
  • [Cites] Gerontologist. 2003 Feb;43(1):62-72 [12604747.001]
  • [Cites] Gerontologist. 2003 Mar;43 Spec No 1:37-46 [12637688.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):643-51 [12672684.001]
  • [Cites] Ethn Health. 2002 Nov;7(4):267-78 [12772546.001]
  • [Cites] Ethn Health. 2003 Feb;8(1):29-39 [12893583.001]
  • [Cites] AIDS Care. 2003 Oct;15(5):717-28 [12959823.001]
  • [Cites] Nicotine Tob Res. 2003 Aug;5(4):575-84 [12959796.001]
  • [Cites] J Community Health. 2003 Dec;28(6):421-37 [14620965.001]
  • [Cites] Appl Nurs Res. 2004 Feb;17(1):55-60 [14991556.001]
  • [Cites] Arch Intern Med. 2004 Apr 12;164(7):801-3 [15078651.001]
  • [Cites] J Law Med Ethics. 2004 Spring;32(1):100-5 [15152431.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4 Suppl):17S-33S [8889351.001]
  • [Cites] J Consult Clin Psychol. 1996 Oct;64(5):861-7 [8916612.001]
  • [Cites] J Consult Clin Psychol. 1996 Oct;64(5):875-80 [8916614.001]
  • [Cites] Ethn Dis. 2005 Winter;15(1):123-9 [15720059.001]
  • [Cites] Annu Rev Public Health. 2005;26:319-39 [15760292.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3112-24 [15860871.001]
  • [Cites] Prev Med. 2005 Jul;41(1):98-101 [15916999.001]
  • [Cites] Evid Rep Technol Assess (Summ). 2005 Jun;(122):1-11 [15989377.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1681-7 [16007244.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5247-54 [16051967.001]
  • [Cites] Clin Trials. 2004;1(4):343-51 [16279272.001]
  • [Cites] PLoS Med. 2006 Feb;3(2):e19 [16318411.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1197-204 [16453333.001]
  • [Cites] Arch Psychiatr Nurs. 2000 Feb;14(1):3-11 [10692801.001]
  • [Cites] Ann Behav Med. 2000 Winter;22(1):89-93 [10892533.001]
  • [Cites] J Natl Med Assoc. 2000 Apr;92(4):169-75 [10976173.001]
  • [Cites] J Natl Med Assoc. 1996 Oct;88(10):630-4 [8918067.001]
  • [Cites] J Natl Med Assoc. 1996 Nov;88(11):701-4 [8961687.001]
  • [Cites] J Gen Intern Med. 1997 Mar;12(3):150-7 [9100139.001]
  • [Cites] Arthritis Care Res. 1997 Feb;10(1):64-71 [9313392.001]
  • [Cites] Am J Public Health. 1997 Nov;87(11):1773-8 [9366634.001]
  • [Cites] J Natl Med Assoc. 1997 Nov;89(11):721-7 [9375475.001]
  • [Cites] Ethn Health. 1997 Mar-Jun;2(1-2):31-45 [9395587.001]
  • [Cites] Am J Prev Med. 1997 Nov-Dec;13(6 Suppl):51-6 [9455594.001]
  • [Cites] Am J Health Promot. 1998 May-Jun;12(5):335-8 [10181143.001]
  • [Cites] Ethn Dis. 1998;8(2):198-208 [9681285.001]
  • [Cites] Ann Behav Med. 1997 Fall;19(4):378-84 [9706365.001]
  • [Cites] Control Clin Trials. 1998 Oct;19(5):461-76 [9741867.001]
  • [Cites] J Epidemiol Community Health. 1998 Jun;52(6):377-84 [9764259.001]
  • [Cites] Prev Med. 1998 Nov-Dec;27(6):838-45 [9922066.001]
  • [Cites] Am J Hypertens. 1999 Jun;12(6):548-54 [10371363.001]
  • [Cites] N Engl J Med. 1999 Jul 15;341(3):198-203 [10403861.001]
  • [Cites] J Gen Intern Med. 1999 Sep;14(9):537-46 [10491242.001]
  • [Cites] Health Educ Behav. 2000 Oct;27(5):632-48 [11009131.001]
  • [Cites] Ann Epidemiol. 2000 Oct;10(7):432-40 [11023622.001]
  • [Cites] Ann Epidemiol. 2000 Nov;10(8 Suppl):S68-77 [11189095.001]
  • [Cites] Ann Epidemiol. 2000 Nov;10(8 Suppl):S78-84 [11189096.001]
  • [Cites] Ann Epidemiol. 2000 Nov;10(8 Suppl):S85-91 [11189097.001]
  • [Cites] Ethn Dis. 2001 Winter;11(1):115-23 [11289232.001]
  • [Cites] J Natl Med Assoc. 2001 Oct;93(10):392-401; discussion 402-4 [11688920.001]
  • [Cites] Control Clin Trials. 2001 Dec;22(6 Suppl):222S-35S [11728626.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):250-4 [11972383.001]
  • [Cites] Ethn Dis. 2002 Spring;12(2):242-51 [12019934.001]
  • [Cites] J Med Ethics. 2004 Jun;30(3):293-8 [15173366.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2720-6 [15187053.001]
  • [Cites] J Asthma. 2004 Jun;41(4):477-84 [15281334.001]
  • [Cites] Control Clin Trials. 2004 Aug;25(4):335-52 [15296809.001]
  • [Cites] J Aging Health. 2004 Nov;16(5):669-87 [15448277.001]
  • [Cites] J Aging Health. 2004 Nov;16(5 Suppl):157S-76S [15448292.001]
  • [Cites] Fam Community Health. 1988 May;11(1):48-59 [10286764.001]
  • [Cites] Prev Med. 1992 Sep;21(5):582-91 [1438108.001]
  • [Cites] Am J Health Promot. 1991 Jan-Feb;5(3):215-21 [10148671.001]
  • [Cites] Health Serv Res. 1995 Apr;30(1 Pt 2):197-205 [7721592.001]
  • [Cites] J Natl Med Assoc. 1995 Apr;87(4):280-7 [7752281.001]
  • [Cites] Image J Nurs Sch. 1995 Fall;27(3):211-5 [7590804.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1747-59 [7473831.001]
  • [Cites] J Community Health. 1996 Apr;21(2):77-87 [8728357.001]
  • [Cites] Prev Med. 1996 Sep-Oct;25(5):547-53 [8888322.001]
  • [Cites] Ann Behav Med. 2002 Spring;24(2):157-66 [12054321.001]
  • [Cites] Control Clin Trials. 2002 Jun;23(3):289-98 [12057880.001]
  • [Cites] Ann Intern Med. 2002 Jul 2;137(1):10-6 [12093240.001]
  • [Cites] Pediatrics. 2002 Sep;110(3):577-82 [12205263.001]
  • [Cites] Arch Intern Med. 2002 Nov 25;162(21):2458-63 [12437405.001]
  • [Cites] Gerontologist. 2003 Feb;43(1):18-26 [12604742.001]
  • (PMID = 17375358.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / P30 AG021342; United States / NIA NIH HHS / AG / P30AG21342
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 82
  • [Other-IDs] NLM/ PMC2219860
  •  go-up   go-down


40. Nadella MV, Shu ST, Dirksen WP, Thudi NK, Nadella KS, Fernandez SA, Lairmore MD, Green PL, Rosol TJ: Expression of parathyroid hormone-related protein during immortalization of human peripheral blood mononuclear cells by HTLV-1: implications for transformation. Retrovirology; 2008 Jun 09;5:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of parathyroid hormone-related protein during immortalization of human peripheral blood mononuclear cells by HTLV-1: implications for transformation.
  • Parathyroid hormone-related protein (PTHrP) plays an important role in the pathogenesis of humoral hypercalcemia of malignancy (HHM) that occurs in the majority of ATLL patients.
  • However, PTHrP is also up-regulated in HTLV-1-carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients without hypercalcemia, indicating that PTHrP is expressed before transformation of T-cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 5;287(4):910-3 [11573951.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(6):1113-36 [11704631.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):249-51 [11860671.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Dec;13(6):455-81 [12401480.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1345-53 [12504010.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1713-6 [12589003.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3963-9 [12907436.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):297-303 [14686486.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Cancer. 1987 Mar 15;59(6):1187-91 [2880656.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] J Clin Invest. 1987 Sep;80(3):911-6 [2887587.001]
  • [Cites] Blood. 1988 Jan;71(1):263-6 [2891388.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(22):8526-30 [2847164.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):1057-60 [2537846.001]
  • [Cites] Nucleic Acids Res. 1989 Jun 12;17(11):4101-15 [2740212.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] EMBO J. 1990 Dec;9(12):4161-6 [2249670.001]
  • [Cites] Eur J Haematol. 1992 May;48(5):278-9 [1644163.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):395-400 [7812198.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2257-67 [7662973.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):702-7 [7669584.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):30857-61 [8537338.001]
  • [Cites] Physiol Rev. 1996 Jan;76(1):127-73 [8592727.001]
  • [Cites] Am J Med Sci. 1996 Dec;312(6):287-94 [8969618.001]
  • [Cites] J Virol. 1997 Feb;71(2):1181-90 [8995640.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:63-4 [9209299.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S23-37 [9379134.001]
  • [Cites] Annu Rev Physiol. 1998;60:431-60 [9558472.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 27;262(2):429-32 [10462492.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:431-45 [15574380.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2005;15(2):115-32 [16022632.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] Blood. 2006 May 15;107(10):3976-82 [16424388.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):170-82 [16223565.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):133-40 [17387298.001]
  • [Cites] J Virol Methods. 2007 Jun;142(1-2):159-68 [17337070.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):135-45 [17372745.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1752-62 [17554373.001]
  • [Cites] J Emerg Med. 2000 Jan;18(1):109-19 [10645850.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):319-24 [10652420.001]
  • [Cites] Immunol Cell Biol. 2000 Aug;78(4):395-402 [10947864.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • (PMID = 18541021.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCI NIH HHS / CA / CA100730-06; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; United States / NCI NIH HHS / CA / P01 CA100730-06; United States / NCRR NIH HHS / RR / T32 RR07073; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CCL3; 0 / Gene Products, tax; 0 / PTH1R protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / Receptor, Parathyroid Hormone, Type 1; 0 / tax protein, Human T-lymphotrophic virus 1
  • [Other-IDs] NLM/ PMC2435116
  •  go-up   go-down


41. Teresi JA, Ocepek-Welikson K, Kleinman M, Cook KF, Crane PK, Gibbons LE, Morales LS, Orlando-Edelen M, Cella D: Evaluating measurement equivalence using the item response theory log-likelihood ratio (IRTLR) method to assess differential item functioning (DIF): applications (with illustrations) to measures of physical functioning ability and general distress. Qual Life Res; 2007;16 Suppl 1:43-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The example for the illustration of the methods came from a study of 1,714 patients with cancer or HIV/AIDS.
  • Further research is needed regarding the criteria and guidelines appropriate for DIF detection in the context of health-related items.

  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Jun 15-30;19(11-12):1651-83 [10844726.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S143-51 [17060821.001]
  • [Cites] Med Care. 2003 Jul;41(7 Suppl):III75-III86 [12865729.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S152-70 [17060822.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S3-4 [17060831.001]
  • [Cites] Stat Med. 2004 Jan 30;23(2):241-56 [14716726.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S107-14 [17060817.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 1998 Sep;53(5):P277-86 [9750564.001]
  • [Cites] J Clin Epidemiol. 2000 Mar 1;53(3):285-9 [10760639.001]
  • [Cites] Psychol Assess. 2002 Mar;14(1):50-9 [11911049.001]
  • [Cites] Qual Life Res. 2007;16 Suppl 1:69-84 [17554640.001]
  • [Cites] Med Care. 2006 Nov;44(11 Suppl 3):S134-42 [17060820.001]
  • [Cites] Arch Phys Med Rehabil. 2004 Jun;85(6):967-71 [15179652.001]
  • [Cites] J Pers Soc Psychol. 2001 Aug;81(2):332-42 [11519936.001]
  • [Cites] J Appl Psychol. 2000 Jun;85(3):451-61 [10900818.001]
  • (PMID = 17484039.001).
  • [ISSN] 0962-9343
  • [Journal-full-title] Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
  • [ISO-abbreviation] Qual Life Res
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG15294; United States / NIAMS NIH HHS / AR / AR052177
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP: Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One; 2008 Jul 09;3(7):e2636
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic adverse events included two cases of erythema nodosum considered to be probably related to the combination of the antigen and the adjuvant.
  • This is the first report that the formulation is associated with systemic adverse events including erythema nodosum.

  • Genetic Alliance. consumer health - Malaria.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. D-MANNITOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vaccine. 2006 Apr 12;24 Suppl 2:S2-44-5 [16823921.001]
  • [Cites] J Biotechnol. 2006 Feb 24;121(4):458-70 [16274825.001]
  • [Cites] PLoS One. 2007;2(9):e850 [17786221.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3406-16 [10999722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):339-44 [11752405.001]
  • [Cites] Chem Immunol. 2002;80:287-307 [12058646.001]
  • [Cites] Protein Expr Purif. 2002 Jun;25(1):87-96 [12071703.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1015-21 [12637465.001]
  • [Cites] Vaccine. 2003 Apr 2;21(15):1650-7 [12639486.001]
  • [Cites] AIDS. 2003 May 23;17(8):1121-6 [12819512.001]
  • [Cites] Expert Rev Vaccines. 2002 Jun;1(1):111-8 [12908518.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD000363 [15106149.001]
  • [Cites] Malar J. 2007;6:107 [17686163.001]
  • [Cites] Vaccine. 2008 Jan 10;26(2):193-200 [18054414.001]
  • [Cites] Parasitology. 2008 Nov;135(13):1497-506 [18257944.001]
  • [Cites] Scott Med J. 1985 Jul;30(3):173 [4059905.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):1042 [2877208.001]
  • [Cites] J Immunol. 1987 Dec 15;139(12):4213-7 [2447164.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1198-9 [2529439.001]
  • [Cites] BMJ. 1990 Aug 11;301(6747):345 [2144199.001]
  • [Cites] J Rheumatol. 1993 Aug;20(8):1417-8 [7901414.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 2:S74-82 [7552517.001]
  • [Cites] N Engl J Med. 1997 Jan 9;336(2):86-91 [8988885.001]
  • [Cites] Vaccine. 1998 Jan-Feb;16(2-3):142-9 [9607022.001]
  • [Cites] J Hum Virol. 1998 May-Jun;1(4):293-8 [10195254.001]
  • [Cites] Vaccine. 1999 Aug 6;17(23-24):3145-59 [10462251.001]
  • [Cites] Vaccine. 2005 Mar 31;23(19):2530-9 [15752840.001]
  • [Cites] Vaccine. 2005 May 2;23(24):3131-8 [15837212.001]
  • [Cites] Infect Immun. 2005 Jun;73(6):3677-85 [15908397.001]
  • [Cites] Trends Parasitol. 2005 Sep;21(9):412-4 [16043410.001]
  • [Cites] Infect Immun. 2005 Dec;73(12):8017-26 [16299295.001]
  • [Cites] Semin Cutan Med Surg. 2007 Jun;26(2):114-25 [17544964.001]
  • (PMID = 18612426.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00295581
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Protozoan; 0 / Antigens, Surface; 0 / Malaria Vaccines; 0 / Oleic Acids; 0 / Pfs25 protein, Plasmodium falciparum; 0 / Protozoan Proteins; 0 / Pvs25 protein, P vivax; 0 / Recombinant Proteins; 0 / Vaccines, Synthetic; 0 / montanide ISA 51; 0 / transmission-Blocking Vaccine based on Pfs25; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ PMC2440546
  •  go-up   go-down


43. Smith A, Lyons A, Pitts M, Croy S, Ryall R, Garland S, Wong ML, Tay EH: Assessing knowledge of human papillomavirus and collecting data on sexual behavior: computer assisted telephone versus face to face interviews. BMC Public Health; 2009;9:429
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Education campaigns seeking to raise awareness of human papillomavirus (HPV) and promoting HPV vaccination depend on accurate surveys of public awareness and knowledge of HPV and related sexual behavior.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2002 Feb;92(2):294-7 [11818309.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Apr;82(4):345-50 [12716319.001]
  • [Cites] Prev Med. 2004 Jun;38(6):745-53 [15193894.001]
  • [Cites] AIDS. 1992 Mar;6(3):315-23 [1567577.001]
  • [Cites] Prev Med. 2008 Feb;46(2):87-98 [17942147.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):627-34 [17497223.001]
  • [Cites] Aust N Z J Public Health. 2007 Jun;31(3):235-42 [17679241.001]
  • [Cites] Sex Health. 2007 Sep;4(3):177-80 [17931530.001]
  • [Cites] BMC Public Health. 2007;7:304 [17961209.001]
  • [Cites] Eur J Public Health. 2005 Feb;15(1):70-7 [15788807.001]
  • (PMID = 19930668.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2787519
  •  go-up   go-down


44. Underwood SM, Buseh AG, Canales MK, Powe B, Dockery B, Kather T, Kent N: Nursing contributions to the elimination of health disparities among African-Americans: review and critique of a decade of research--Part III. J Natl Black Nurses Assoc; 2005 Dec;16(2):35-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several reports have been published in the peer-reviewed literature that describe the outcomes of nurse-directed studies aimed at addressing the factors associated with the disparities experienced by African-Americans and these reports were also aimed toward the design of interventions to reduce and/or eliminate them.
  • This report presents the results of a review, analysis, and critique of reports of outcomes of nursing research aimed toward reducing health-related disparities among African-Americans.
  • This knowledge is relative to the individual and familial impact of cardiovascular disease, cancer, diabetes, HIV/AIDS, mental health and mental illness, and sickle cell disease within the African-American community.

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570644.001).
  • [ISSN] 0885-6028
  • [Journal-full-title] Journal of National Black Nurses' Association : JNBNA
  • [ISO-abbreviation] J Natl Black Nurses Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 120
  •  go-up   go-down


45. Nyagol J, De Falco G, Lazzi S, Luzzi A, Cerino G, Shaheen S, Palummo N, Bellan C, Spina D, Leoncini L: HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop; 2008 Jul;1(1):3-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.
  • We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).
  • Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]
  • [Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]
  • [Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]
  • [Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]
  • [Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]
  • [Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]
  • [Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]
  • [Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]
  • [Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]
  • [Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]
  • [Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]
  • [Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]
  • [Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]
  • [Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]
  • [Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]
  • [Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]
  • (PMID = 19669199.001).
  • [ISSN] 1868-9256
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2712328
  •  go-up   go-down


46. Baydoun HH, Pancewicz J, Bai X, Nicot C: HTLV-I p30 inhibits multiple S phase entry checkpoints, decreases cyclin E-CDK2 interactions and delays cell cycle progression. Mol Cancer; 2010 Nov 23;9:302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: In contrast to HTLV-I, the HTLV-II-related retrovirus is not oncogenic in humans.
  • Here we report that the HTLV-I p30 delays cell cycle progression while its homologue, HTLV-II p28, does not, providing evidence for important differences between these two related retrovirus proteins.


47. Ferreira VP, Pangburn MK, Cortés C: Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol; 2010 Aug;47(13):2187-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inadequate recognition of host cell surfaces by factor H due to mutations and polymorphisms have been associated with complement-mediated tissue damage and disease.
  • On the other hand, unwanted recognition of pathogens and altered self-cells (i.e. cancer) by factor H is used as an immune evasion strategy.
  • This review will focus on the current knowledge related to these versatile recognition properties of factor H.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Immunol. 2000 May 1;164(9):4742-51 [10779780.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):6075-81 [10820293.001]
  • [Cites] Am J Hum Genet. 2000 May;66(5):1721-2 [10762557.001]
  • [Cites] Pediatr Nephrol. 2000 Sep;14(10-11):1045-53 [10975323.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27657-62 [10837479.001]
  • [Cites] Mol Immunol. 1995 Jul;32(10):711-6 [7659097.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Aug;11(8):971-80 [7492444.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 May;11(5):577-88 [7576914.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5663-70 [7499851.001]
  • [Cites] Immunobiology. 1995 Jun;193(1):98-113 [7590866.001]
  • [Cites] Science. 1996 Apr 5;272(5258):50-3 [8600536.001]
  • [Cites] J Immunol. 1996 Jul 15;157(2):884-91 [8752942.001]
  • [Cites] FEBS Lett. 1996 Sep 16;393(2-3):297-302 [8814308.001]
  • [Cites] Adv Immunol. 1996;61:201-83 [8834497.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10996-1001 [8855297.001]
  • [Cites] Eur J Immunol. 1996 Oct;26(10):2383-7 [8898949.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5422-7 [8955190.001]
  • [Cites] Infect Immun. 1997 Feb;65(2):484-7 [9009301.001]
  • [Cites] J Immunol. 1997 Apr 15;158(8):3779-86 [9103443.001]
  • [Cites] Nature. 1997 Jul 24;388(6640):323-4 [9237746.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):743-52 [9480984.001]
  • [Cites] Biochem J. 1998 Apr 1;331 ( Pt 1):41-7 [9512460.001]
  • [Cites] Infect Immun. 1998 Apr;66(4):1427-31 [9529063.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3342-8 [9531293.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3349-54 [9531294.001]
  • [Cites] Kidney Int. 1998 Apr;53(4):836-44 [9551389.001]
  • [Cites] J Immunol. 1998 Apr 15;160(8):4057-66 [9558116.001]
  • [Cites] Transfusion. 1998 Apr;38(4):337-42 [9595015.001]
  • [Cites] Annu Rev Immunol. 1998;16:545-68 [9597141.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):671-80 [9705949.001]
  • [Cites] Biochem J. 1999 Jul 1;341 ( Pt 1):61-9 [10377245.001]
  • [Cites] Immunopharmacology. 1999 May;42(1-3):23-30 [10408362.001]
  • [Cites] Immunopharmacology. 1999 May;42(1-3):53-60 [10408366.001]
  • [Cites] Infect Immun. 1999 Sep;67(9):4517-24 [10456894.001]
  • [Cites] J Immunol. 1959 Oct;83:428-36 [14415902.001]
  • [Cites] Infect Immun. 2005 Apr;73(4):2351-9 [15784581.001]
  • [Cites] Science. 2005 Apr 15;308(5720):419-21 [15761120.001]
  • [Cites] Science. 2005 Apr 15;308(5720):421-4 [15761121.001]
  • [Cites] Science. 2005 Apr 15;308(5720):385-9 [15761122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32 [15870199.001]
  • [Cites] Am J Pathol. 2005 Oct;167(4):1173-81 [16192651.001]
  • [Cites] Microb Pathog. 2005 Oct;39(4):139-47 [16169184.001]
  • [Cites] Infect Immun. 2005 Nov;73(11):7126-32 [16239506.001]
  • [Cites] Clin Immunol. 2006 Feb-Mar;118(2-3):127-36 [16338172.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):292-3 [16470555.001]
  • [Cites] Mol Immunol. 2006 Apr;43(10):1624-32 [16263173.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1784-94 [16601698.001]
  • [Cites] Infect Immun. 2006 May;74(5):2659-66 [16622202.001]
  • [Cites] Curr Opin Genet Dev. 2006 Jun;16(3):317-22 [16650759.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7566-75 [16751403.001]
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16512-20 [16533809.001]
  • [Cites] J Leukoc Biol. 2006 Aug;80(2):237-44 [16769769.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24713-20 [16787919.001]
  • [Cites] Mol Microbiol. 2006 Sep;61(5):1220-36 [16925556.001]
  • [Cites] J Immunol. 2006 Nov 1;177(9):6308-16 [17056561.001]
  • [Cites] Nature. 2006 Nov 9;444(7116):217-20 [17051150.001]
  • [Cites] Wien Klin Wochenschr. 2006 Nov;118(21-22):669-76 [17160605.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19111-6 [17132743.001]
  • [Cites] Br Med Bull. 2006;77-78:5-22 [16968692.001]
  • [Cites] Infect Immun. 2007 Feb;75(2):1050-4 [17101650.001]
  • [Cites] Mol Immunol. 2007 Apr;44(10):2697-706 [17208302.001]
  • [Cites] J Immunol. 2007 Mar 15;178(6):3831-6 [17339482.001]
  • [Cites] Exp Eye Res. 2007 Apr;84(4):635-45 [17292886.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4489-97 [17372007.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):10894-900 [17293598.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5848-58 [17442969.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5991-8 [17442984.001]
  • [Cites] Mol Immunol. 2007 Jul;44(13):3398-406 [17399790.001]
  • [Cites] Am J Hum Genet. 1999 Dec;65(6):1538-46 [10577907.001]
  • [Cites] Annu Rev Med. 2008;59:293-309 [17705684.001]
  • [Cites] Clin Exp Immunol. 2008 Feb;151(2):210-30 [18190458.001]
  • [Cites] Infect Immun. 2008 Feb;76(2):820-7 [18039838.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3426-35 [18292569.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2030-7 [18183578.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7613-21 [18490764.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):537-45 [18566420.001]
  • [Cites] J Leukoc Biol. 2008 Jul;84(1):77-85 [18430786.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9023-8 [18579773.001]
  • [Cites] Immunol Rev. 2008 Jun;223:300-16 [18613844.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2610-9 [18684951.001]
  • [Cites] Infect Immun. 2008 Sep;76(9):4100-9 [18625735.001]
  • [Cites] Curr Opin Lipidol. 2008 Oct;19(5):478-82 [18769228.001]
  • [Cites] Infect Immun. 2008 Nov;76(11):5016-27 [18765735.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):30451-60 [18786923.001]
  • [Cites] Platelets. 2008 Nov;19(7):512-9 [18979363.001]
  • [Cites] J Immunol. 2008 Dec 1;181(11):8068-76 [19017999.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8433-40 [19050261.001]
  • [Cites] J Immunol. 2008 Dec 15;181(12):8624-32 [19050282.001]
  • [Cites] PLoS Pathog. 2008 Dec;4(12):e1000250 [19112495.001]
  • [Cites] J Immunol. 2009 Jan 15;182(2):1061-8 [19124749.001]
  • [Cites] Thromb Haemost. 2009 Feb;101(2):227-32 [19190803.001]
  • [Cites] Clin Nephrol. 2009 Feb;71(2):110-7 [19203502.001]
  • [Cites] Ann Surg. 2009 Feb;249(2):310-7 [19212187.001]
  • [Cites] Infect Immun. 2009 Apr;77(4):1417-25 [19204088.001]
  • [Cites] J Immunol. 2009 Apr 1;182(7):4368-77 [19299737.001]
  • [Cites] Nature. 2009 Apr 16;458(7240):890-3 [19225461.001]
  • [Cites] Infect Immun. 2009 May;77(5):2094-103 [19273554.001]
  • [Cites] Vaccine. 2008 Dec 30;26 Suppl 8:I9-14 [19388158.001]
  • [Cites] Vaccine. 2008 Dec 30;26 Suppl 8:I15-21 [19388159.001]
  • [Cites] Biochim Biophys Acta. 2009 May;1790(5):361-7 [19306911.001]
  • [Cites] J Immunol. 2009 Jun 1;182(11):7009-18 [19454698.001]
  • [Cites] J Biol Chem. 2009 Jun 5;284(23):15650-8 [19351878.001]
  • [Cites] Scand J Immunol. 2009 May;69(5):457-64 [19508377.001]
  • [Cites] J Biol Chem. 2009 Jun 19;284(25):16939-47 [19386604.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3056-64 [19264882.001]
  • [Cites] J Mol Biol. 2009 Aug 7;391(1):119-35 [19505474.001]
  • [Cites] J Mol Biol. 2009 Aug 7;391(1):98-118 [19505476.001]
  • [Cites] Cancer Immunol Immunother. 2009 Nov;58(11):1771-80 [19259664.001]
  • [Cites] Infect Immun. 2009 Sep;77(9):3886-93 [19528206.001]
  • [Cites] Hum Mol Genet. 2009 Sep 15;18(18):3452-61 [19549636.001]
  • [Cites] J Immunol. 2009 Nov 1;183(9):5928-37 [19828624.001]
  • [Cites] J Inorg Biochem. 2009 Nov;103(11):1591-5 [19540598.001]
  • [Cites] Mol Immunol. 2009 Dec;47(2-3):185-95 [19800693.001]
  • [Cites] Mol Immunol. 2009 Dec;47(2-3):541-50 [19850343.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4538-45 [19704120.001]
  • [Cites] Nephrol Dial Transplant. 2010 Jan;25(1):136-44 [19666655.001]
  • [Cites] Diabetes. 2010 Jan;59(1):200-9 [19833879.001]
  • [Cites] J Biol Chem. 2010 Jan 8;285(2):1053-65 [19850925.001]
  • [Cites] J Immunol. 2010 Jan 15;184(2):912-21 [20008295.001]
  • [Cites] J Biol Chem. 2010 Jan 15;285(3):2184-92 [19920146.001]
  • [Cites] Pediatr Nephrol. 2010 Jan;25(1):97-104 [19856002.001]
  • [Cites] J Biol Chem. 2010 Feb 5;285(6):3766-76 [19951950.001]
  • [Cites] FEMS Microbiol Lett. 2009 Dec;301(2):224-31 [19878322.001]
  • [Cites] Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S54-65 [20144017.001]
  • [Cites] Annu Rev Immunol. 2010;28:131-55 [19947883.001]
  • [Cites] Am J Kidney Dis. 2010 Apr;55(4):708-11 [19854549.001]
  • [Cites] J Immunol. 2010 Jul 1;185(1):507-16 [20530262.001]
  • [Cites] Immunobiology. 2010 Nov;215(11):932-40 [20382442.001]
  • [Cites] Stem Cells Dev. 2010 Nov;19(11):1803-9 [20163251.001]
  • [Cites] Am J Kidney Dis. 1994 Dec;24(6):936-41 [7985673.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1054-61 [7883953.001]
  • [Cites] AIDS. 1995 Jan;9(1):19-26 [7893437.001]
  • [Cites] J Immunol. 1995 Jul 1;155(1):348-56 [7541419.001]
  • [Cites] Regul Pept. 2003 Apr 15;112(1-3):121-30 [12667633.001]
  • [Cites] J Clin Invest. 2003 Apr;111(8):1181-90 [12697737.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3905-10 [12904415.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2421-9 [14607842.001]
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):787-95 [14978182.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3111-8 [14978117.001]
  • [Cites] Am J Ophthalmol. 2004 Mar;137(3):486-95 [15013873.001]
  • [Cites] J Bacteriol. 2004 May;186(9):2612-8 [15090501.001]
  • [Cites] Mol Immunol. 2004 Jun;41(4):355-67 [15163532.001]
  • [Cites] Immunogenetics. 2004 May;56(2):77-82 [15118848.001]
  • [Cites] Indian J Med Res. 2004 May;119 Suppl:66-73 [15232165.001]
  • [Cites] Blood. 1971 May;37(5):556-62 [5554213.001]
  • [Cites] J Exp Med. 1972 Apr 1;135(4):1003-8 [4111773.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 [1067618.001]
  • [Cites] J Exp Med. 1976 Nov 2;144(5):1147-63 [62817.001]
  • [Cites] J Exp Med. 1977 Jul 1;146(1):257-70 [301546.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5 [273923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20 [276881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Aug;75(8):3948-52 [279011.001]
  • [Cites] J Exp Med. 1979 Nov 1;150(5):1202-15 [501288.001]
  • [Cites] Mol Immunol. 1980 Jan;17(1):9-20 [7360115.001]
  • [Cites] Biochem Biophys Res Commun. 1980 May 14;94(1):61-7 [6248066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5764-8 [6934510.001]
  • [Cites] Acta Paediatr Scand. 1981 Sep;70(5):705-10 [6459707.001]
  • [Cites] Springer Semin Immunopathol. 1984;7(2-3):163-92 [6238433.001]
  • [Cites] Biochem J. 1984 Dec 1;224(2):389-98 [6240261.001]
  • [Cites] J Exp Med. 1985 May 1;161(5):1189-95 [3157763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(11):3963-7 [2940596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Sep;83(17):6593-7 [2944112.001]
  • [Cites] J Exp Med. 1987 Apr 1;165(4):1095-112 [2951479.001]
  • [Cites] J Immunol Methods. 1987 Aug 24;102(1):7-14 [3624878.001]
  • [Cites] Eur J Immunol. 1987 Oct;17(10):1485-9 [2445583.001]
  • [Cites] Biochem J. 1988 Jan 15;249(2):593-602 [2963625.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] Annu Rev Biochem. 1988;57:321-47 [3052276.001]
  • [Cites] Annu Rev Microbiol. 1988;42:201-30 [3059994.001]
  • [Cites] Eur J Immunol. 1989 Nov;19(11):2145-50 [2480904.001]
  • [Cites] Curr Top Microbiol Immunol. 1990;153:147-62 [2137073.001]
  • [Cites] Curr Top Microbiol Immunol. 1990;153:209-22 [2404695.001]
  • [Cites] Curr Top Microbiol Immunol. 1990;153:73-82 [1688756.001]
  • [Cites] J Immunol. 1990 May 15;144(10):3835-40 [2139673.001]
  • [Cites] J Exp Med. 2000 Nov 6;192(9):1353-64 [11067883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(10):3982-6 [1692629.001]
  • [Cites] Biochemistry. 1991 Mar 19;30(11):2847-57 [1826087.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16847-53 [1832158.001]
  • [Cites] Clin Exp Immunol. 1991 Oct;86 Suppl 1:27-30 [1718640.001]
  • [Cites] J Immunol. 1992 Oct 15;149(8):2592-9 [1401896.001]
  • [Cites] Infect Immun. 1993 Aug;61(8):3129-36 [8335343.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):28997-9002 [7961863.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):7292-301 [17513779.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1249-56 [17517971.001]
  • [Cites] J Biol Chem. 2007 Jun 29;282(26):18960-8 [17360715.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2600-8 [17675523.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):2979-88 [17709513.001]
  • [Cites] J Am Soc Nephrol. 2007 Sep;18(9):2447-56 [17675665.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2190-2 [17554058.001]
  • [Cites] PLoS One. 2007;2(11):e1188 [18000555.001]
  • [Cites] J Mol Biol. 2008 Jan 4;375(1):80-101 [18005991.001]
  • [Cites] Clin Exp Immunol. 2008 Jan;151(1):1-13 [18081690.001]
  • [Cites] Clin Exp Immunol. 2008 Jan;151(1):14-24 [18081691.001]
  • [Cites] J Biol Chem. 2007 Dec 28;282(52):37537-44 [17959597.001]
  • [Cites] Mol Immunol. 2008 Mar;45(5):1485-93 [17915330.001]
  • [Cites] Mol Immunol. 2008 Mar;45(5):1199-207 [17961651.001]
  • [Cites] J Mol Biol. 2008 Jan 25;375(4):891-900 [18054958.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37257-63 [10967103.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):478-84 [11170895.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):485-90 [11170896.001]
  • [Cites] J Am Soc Nephrol. 2001 Feb;12(2):297-307 [11158219.001]
  • [Cites] Curr Opin Hematol. 2001 Mar;8(2):61-7 [11224678.001]
  • [Cites] Infect Immun. 2001 May;69(5):3435-7 [11292770.001]
  • [Cites] Eur J Immunol. 2001 Jun;31(6):1674-84 [11385611.001]
  • [Cites] J Mol Biol. 2001 Jun 22;309(5):1117-38 [11399083.001]
  • [Cites] Immunol Rev. 2001 Apr;180:146-61 [11414356.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7800-9 [11705962.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] J Mol Biol. 2002 Feb 15;316(2):217-24 [11851332.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12642-8 [11812795.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13700-8 [11825898.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1786-93 [12085326.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):424-8 [12091909.001]
  • [Cites] Infect Immun. 2002 Sep;70(9):5185-92 [12183569.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5604-11 [12228288.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):4702-6 [12391176.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1119-27 [12402151.001]
  • [Cites] Eur J Immunol. 2003 Mar;33(3):697-707 [12616490.001]
  • [Cites] Hypertens Res. 2003 Feb;26 Suppl:S55-9 [12630812.001]
  • (PMID = 20580090.001).
  • [ISSN] 1872-9142
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P30 HL101317; United States / NIDDK NIH HHS / DK / DK035081-26; United States / NHLBI NIH HHS / HL / P30 HL101317-01; United States / NHLBI NIH HHS / HL / HL101317-01; United States / NIDDK NIH HHS / DK / R37 DK035081; United States / NHLBI NIH HHS / HL / 1P30HL101317-01; United States / NIDDK NIH HHS / DK / DK-35081; United States / NIDDK NIH HHS / DK / R01 DK035081-26; United States / NIDDK NIH HHS / DK / R01 DK035081
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 80295-43-8 / Complement C3b; 80295-45-0 / Complement C3d; 80295-65-4 / Complement Factor H
  • [Number-of-references] 227
  • [Other-IDs] NLM/ NIHMS206344; NLM/ PMC2921957
  •  go-up   go-down


48. Colón-López V, Ortiz AP, Palefsky J: Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men. P R Health Sci J; 2010 Sep;29(3):232-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men.
  • Over the last two decades, research has established a strong causal link between specific types of HPV infection and cancer, particularly cervical, anal, vulvar/vaginal, penile, and oropharyngeal cancer.
  • With the world-wide introduction of two new prophylactic vaccines against high-risk HPVs causing cervical cancer, and the recent FDA approval of the quadrivalent vaccine in preventing genital warts in men, there is an urgency to determine the burden of HPV in Hispanic populations before vaccine programs are implemented on a widespread basis.
  • This review article summarizes existing research on HPV infection and HPV-related morbidities in men, with a particular emphasis on Hispanic men in the United States and Puerto Rico.
  • (1) genital warts, (2) HPV and related cancers and (3) biobehavioral and psychosocial factors related to HPV infection and vaccination.

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Board Fam Med. 2009 Jan-Feb;22(1):34-42 [19124631.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):362-71 [19133808.001]
  • [Cites] Int J Cancer. 2009 Mar 15;124(6):1251-7 [19089913.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):180-8 [19221247.001]
  • [Cites] J Infect Dis. 2009 Apr 1;199(7):965-73 [19239366.001]
  • [Cites] Curr Opin HIV AIDS. 2009 Jan;4(1):52-6 [19339939.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1077-83 [19318438.001]
  • [Cites] J Infect Dis. 2009 May 1;199(9):1263-9 [19320589.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] BMC Cancer. 2009;9:129 [19400958.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2009 Jun 5;58(21):589-91 [19498337.001]
  • [Cites] Contraception. 2009 Aug;80(2):158-62 [19631791.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2009 Aug;22(4):205-15 [19646665.001]
  • [Cites] Public Health Genomics. 2009;12(5-6):291-307 [19684442.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Ethn Health. 2009 Dec;14(6):607-24 [19953392.001]
  • [Cites] Int J Epidemiol. 2010 Feb;39(1):166-81 [20022926.001]
  • [Cites] Gynecol Oncol. 2010 May;117(2 Suppl):S15-9 [20138345.001]
  • [Cites] J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9 [20307839.001]
  • [Cites] J Infect Dis. 2010 May 1;201(9):1340-3 [20350160.001]
  • [Cites] Sex Transm Dis. 2010 Jun;37(6):386-91 [20081557.001]
  • [Cites] Sex Transm Infect. 2010 Jun;86(3):241-6 [19951936.001]
  • [Cites] Lancet Oncol. 2010 Aug;11(8):781-9 [20451455.001]
  • [Cites] P R Health Sci J. 2010 Sep;29(3):241-9 [20799511.001]
  • [Cites] J Community Health. 2000 Feb;25(1):67-78 [10706210.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):106-15 [10889929.001]
  • [Cites] Int J STD AIDS. 2001 Apr;12(4):211-5 [11319969.001]
  • [Cites] Sex Transm Dis. 2001 May;28(5):277-80 [11354266.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):46-54 [11437401.001]
  • [Cites] Am J Public Health. 2002 Mar;92(3):378-81 [11867314.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):705-11 [11875730.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1105-12 [11948269.001]
  • [Cites] Sex Transm Infect. 2002 Jun;78(3):215-8 [12238658.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1064-70 [12660920.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10 [14982671.001]
  • [Cites] Herpes. 2004 Apr;11(1):8-11 [15115631.001]
  • [Cites] Epidemiol Rev. 2004;26:22-35 [15234945.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):171-9 [15249566.001]
  • [Cites] Head Neck. 2004 Sep;26(9):778-84 [15350023.001]
  • [Cites] Sex Transm Dis. 2004 Oct;31(10):601-7 [15388997.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):453-71 [15489139.001]
  • [Cites] Int J Addict. 1990 Jun;25(6):665-91 [2265869.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):353-61 [9237700.001]
  • [Cites] Genitourin Med. 1997 Jun;73(3):174-80 [9306896.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):27-33 [10334639.001]
  • [Cites] J Infect Dis. 2005 Feb 1;191 Suppl 1:S42-54 [15627230.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):311-5 [15716837.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6 [16030106.001]
  • [Cites] Int J STD AIDS. 2005 Oct;16(10):667-70 [16212712.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1934-9 [16708372.001]
  • [Cites] Braz J Otorhinolaryngol. 2006 Mar-Apr;72(2):272-82 [16951865.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] J Infect Dis. 2006 Oct 15;194(8):1044-57 [16991079.001]
  • [Cites] Sex Transm Dis. 2007 Jul;34(7):479-84 [17413536.001]
  • [Cites] Dis Markers. 2007;23(4):261-72 [17627061.001]
  • [Cites] Cir Cir. 2007 May-Jun;75(3):151-5 [17659164.001]
  • [Cites] Prev Med. 2007 Aug-Sep;45(2-3):107-14 [17628649.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1429-35 [17724670.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S2-5 [17938014.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S24-6 [17938015.001]
  • [Cites] Arch Med Res. 2008 Feb;39(2):189-97 [18164962.001]
  • [Cites] Sex Transm Dis. 2008 Apr;35(4):357-60 [18360316.001]
  • [Cites] Am J Obstet Gynecol. 2008 May;198(5):500.e1-7 [18455524.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K17-28 [18847554.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K53-61 [18847557.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2883-91 [18980292.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2892-900 [18980293.001]
  • [Cites] Sex Transm Dis. 2009 Jan;36(1):58-62 [18830138.001]
  • (PMID = 20799510.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R03 DA027939-01; United States / NCI NIH HHS / CA / 5R25CA094186-08; United States / NCI NIH HHS / SC / SC2 AI090922-01; United States / NCI NIH HHS / SC / 1 SC2 AI090922-01; United States / NCI NIH HHS / CA / R25 CA094186; United States / NCI NIH HHS / CA / U54 CA096297; United States / NIAID NIH HHS / AI / SC2 AI090922; United States / NIDA NIH HHS / DA / R03 DA027939; United States / NCRR NIH HHS / RR / G12 RR003051-21; United States / NCRR NIH HHS / RR / G12 RR003051; United States / PHS HHS / / R03 027939-01; United States / NIAID NIH HHS / AI / SC2 AI090922-01; United States / NCRR NIH HHS / RR / G12RR03051; United States / NCI NIH HHS / CA / R25 CA094186-08; United States / NIMHD NIH HHS / MD / G12 MD007600; United States / NCI NIH HHS / CA / U54 CA096297-05; United States / NCI NIH HHS / CA / U54CA96297
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Puerto Rico
  • [Number-of-references] 99
  • [Other-IDs] NLM/ NIHMS266486; NLM/ PMC3038604
  •  go-up   go-down


49. Pan H, Xie J, Ye F, Gao SJ: Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection. J Virol; 2006 Jun;80(11):5371-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is etiologically associated with Kaposi's sarcoma, a dominant AIDS-related tumor of endothelial cells, and several other lymphoproliferative malignancies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:137-66 [9891781.001]
  • [Cites] Science. 1999 Aug 13;285(5430):1028-32 [10446041.001]
  • [Cites] J Virol. 2004 Dec;78(23):13381-90 [15542692.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Apr;79(8):4952-64 [15795281.001]
  • [Cites] J Virol. 2005 Aug;79(16):10138-46 [16051806.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2003 Jul;77(14):7707-12 [12829809.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Sep;77(18):9738-49 [12941882.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):3025-35 [15024089.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Jul;287(1):C200-8 [15013949.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5227-41 [15122343.001]
  • [Cites] J Gen Virol. 2004 Aug;85(Pt 8):2347-56 [15269376.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] J Virol. 2004 Nov;78(21):11615-21 [15479802.001]
  • [Cites] J Virol. 2004 Nov;78(21):11798-806 [15479821.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1025-37 [8137421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3844-8 [8170999.001]
  • [Cites] Biochim Biophys Acta. 1995 Mar 16;1265(2-3):224-7 [7696354.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6641-6 [8692871.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18586-94 [9228025.001]
  • [Cites] J Virol. 2005 Oct;79(20):13180-5 [16189019.001]
  • [Cites] Virology. 2005 Dec 5;343(1):47-64 [16154170.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12023-31 [11821384.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7888-93 [10884420.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22607-10 [10801899.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23333-9 [10816598.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4119-24 [11274437.001]
  • [Cites] Traffic. 2001 Jun;2(6):375-84 [11389765.001]
  • [Cites] Virology. 2001 Jul 20;286(1):91-9 [11448162.001]
  • [Cites] Cell. 2001 Jul 13;106(1):1-4 [11461694.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38353-60 [11459835.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2449-76 [11749383.001]
  • [Cites] Biochem J. 2002 Mar 1;362(Pt 2):367-73 [11853544.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Crit Rev Immunol. 2001;21(4):311-22 [11922076.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] J Virol. 2002 Jul;76(13):6689-700 [12050382.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):556-64 [12134156.001]
  • [Cites] Mol Cells. 2002 Oct 31;14(2):185-91 [12442889.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] J Virol. 2003 May;77(9):5241-52 [12692226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • (PMID = 16699017.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096512; United States / NIDCR NIH HHS / DE / R01 DE017333; United States / NCI NIH HHS / CA / CA 096512; United States / NIDCR NIH HHS / DE / DE 017333
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1
  • [Other-IDs] NLM/ PMC1472170
  •  go-up   go-down


50. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM: A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. J Virol; 2009 Dec;83(24):12738-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.
  • We created a hybrid adeno-associated virus (AAV) from two related rhesus macaque isolates, called AAVrh32.33, and evaluated it as a vaccine carrier for human immunodeficiency virus type 1 (HIV-1) and type A influenza virus antigens.

  • MedlinePlus Health Information. consumer health - Flu Shot.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2003 Aug;77(15):8263-71 [12857895.001]
  • [Cites] Clin Med Res. 2005 Nov;3(4):234-40 [16303889.001]
  • [Cites] Blood. 2004 Jan 1;103(1):85-92 [12969984.001]
  • [Cites] Annu Rev Med. 2004;55:355-72 [14746526.001]
  • [Cites] J Clin Immunol. 2004 Mar;24(2):162-9 [15024183.001]
  • [Cites] Hum Gene Ther. 2004 Apr;15(4):405-13 [15053865.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1810-7 [16249376.001]
  • [Cites] J Virol. 2006 Mar;80(6):2621-30 [16501072.001]
  • [Cites] Hum Gene Ther. 2006 Apr;17(4):427-39 [16610930.001]
  • [Cites] Hum Gene Ther. 2006 May;17(5):500-6 [16716107.001]
  • [Cites] J Virol. 2006 Jun;80(12):6192-4 [16731960.001]
  • [Cites] J Virol. 2006 Dec;80(24):11899-910 [17005662.001]
  • [Cites] Gene Ther. 2007 Mar;14(5):429-40 [17066096.001]
  • [Cites] Mol Ther. 2007 Jun;15(6):1203-10 [17375069.001]
  • [Cites] Vaccine. 2007 Jul 9;25(28):5220-31 [17559989.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1132-40 [17438084.001]
  • [Cites] J Biomed Sci. 2007 Sep;14(5):585-94 [17387636.001]
  • [Cites] Nat Protoc. 2007;2(9):2057-67 [17853861.001]
  • [Cites] J Virol. 2007 Nov;81(21):11840-9 [17715240.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3958-70 [18008010.001]
  • [Cites] Hum Gene Ther. 2008 Jul;19(7):663-9 [18549307.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):381-90 [19133809.001]
  • [Cites] J Immunol. 2009 May 15;182(10):6051-60 [19414756.001]
  • [Cites] Hepatology. 2009 Aug;50(2):612-21 [19575456.001]
  • [Cites] Gene Ther. 2009 Dec;16(12):1416-28 [19727141.001]
  • [Cites] J Virol. 2004 Jun;78(12):6344-59 [15163728.001]
  • [Cites] AIDS. 2004 May 21;18(8):1213-6 [15166541.001]
  • [Cites] J Alzheimers Dis. 2004 Oct;6(5):483-8 [15505369.001]
  • [Cites] Gene Ther. 2004 Nov;11(22):1617-26 [15295617.001]
  • [Cites] Vaccine. 1999 Feb 26;17(7-8):933-43 [10067700.001]
  • [Cites] Clin Immunol. 1999 Jul;92(1):67-75 [10413654.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):93-100 [15386434.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1424-30 [15507527.001]
  • [Cites] J Virol. 2000 Mar;74(5):2420-5 [10666273.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):5236-44 [11290808.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3733-7 [11389010.001]
  • [Cites] Hum Gene Ther. 2001 Jun 10;12(9):1047-61 [11399227.001]
  • [Cites] J Gene Med. 2001 May-Jun;3(3):260-70 [11437331.001]
  • [Cites] Blood. 2002 Jan 15;99(2):600-8 [11781244.001]
  • [Cites] J Gene Med. 2002 Jan-Feb;4(1):46-53 [11828387.001]
  • [Cites] Hum Gene Ther. 2002 Jul 20;13(11):1281-91 [12162811.001]
  • [Cites] Hum Gene Ther. 2002 Sep 1;13(13):1571-81 [12228012.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4281-9 [12682263.001]
  • [Cites] J Virol. 2003 Jun;77(11):6305-13 [12743287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):6081-6 [12716974.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3079-86 [15637142.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4226-34 [15713796.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7179-85 [15905562.001]
  • [Cites] J Virol. 2005 Aug;79(16):10108-25 [16051804.001]
  • [Cites] Gene Ther. 2005 Oct;12(19):1453-64 [15889137.001]
  • [Cites] Infect Immun. 2005 Oct;73(10):6885-91 [16177368.001]
  • [Cites] Gene Ther. 2003 Oct;10(21):1807-13 [12960970.001]
  • (PMID = 19812149.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / N01AI30034; United States / NIAID NIH HHS / AI / AI-30034; United States / NIDDK NIH HHS / DK / P30-DK-47757; United States / NIDDK NIH HHS / DK / P30 DK047757; United States / NHLBI NIH HHS / HL / P01-HL-059407; United States / NHLBI NIH HHS / HL / P01 HL059407
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / Influenza Vaccines; 0 / Vaccines, Synthetic; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2786857
  •  go-up   go-down


51. Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics; 2005;23(11):1107-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
  • Comprehensive estimates of the annual economic burden associated with the prevention and treatment of anogenital HPV-related disease in the US population are currently unavailable.
  • The purpose of this paper is to (i) outline an analytic framework from which to estimate the annual economic burden of preventing and treating anogenital HPV-related disease in the US;.
  • Among eight US studies identified that describe the annual economic burden pertaining to one or more aspects of anogenital HPV-related disease, three met the review eligibility criteria (published between 1990 and 2004, examined multiple facets of annual anogenital HPV-related economic burden, and clearly articulated the data and methods used in the estimation process).
  • Estimates of the annual direct medical costs associated with cervical cancer were comparable across studies (range 300-400 million US dollars).
  • In contrast, there was a wide range across studies for estimates of the annual direct medical costs associated with cervical intraepithelial neoplasia (range 700 million US dollars-2.3 billion US dollars).
  • Only one study reported direct medical costs for anogenital warts (200 million US dollars) and routine cervical cancer screening (2.3 billion US dollars).
  • No studies examined direct medical costs attributable to HPV-related anal, penile, vaginal or vulvar cancers, or the work and productivity losses resulting from time spent receiving medical care, morbidity or mortality.
  • Current economic burden estimates would suggest annual direct medical costs associated with the prevention and treatment of anogenital warts and cervical HPV-related disease of at least 4 billion US dollars.
  • This figure would likely rise to at least 5 billion US dollars per year if direct medical costs associated with other disease entities caused by the sexual transmission of HPV were included, with further additions to the economic burden totalling in the billions of dollars if work and productivity losses were incorporated, a research priority for future studies.


52. Barskova T, Oesterreich R: Post-traumatic growth in people living with a serious medical condition and its relations to physical and mental health: a systematic review. Disabil Rehabil; 2009;31(21):1709-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The majority of the studies investigated PTG and its relationships to health indicators after the diagnosis of cancer, HIV/AIDS, cardiac disease, multiple sclerosis and rheumatoid arthritis.
  • The review indicated that quality of social support, patients' coping strategies and several indicators of mental and physical health were consistently associated with post-traumatic growth.
  • Associations between growth and health-related variables (e.g. physical deficits, pain, depression, anxiety) varied depending on different study design (cross-sectional versus longitudinal) and the sample composition (patients versus symptom-free survivors).
  • More research is needed to investigate specific disease-related profiles of PTG and the complex mechanisms, which underlie the relationships between PTG and the process of convalescence.

  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350430.001).
  • [ISSN] 0963-8288
  • [Journal-full-title] Disability and rehabilitation
  • [ISO-abbreviation] Disabil Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


53. Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, Lokshin AE, Zeleniuch-Jacquotte A: Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control; 2010 Aug;21(8):1323-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytokines play important roles in B-cell activation, proliferation, and apoptosis, thus may be etiologically related to risk of B-cell non-Hodgkin lymphoma (B-NHL).
  • Three other cytokines were marginally associated with risk of B-NHL: TNF-alpha (OR = 1.7, 95% CI = 0.9-3.3, p (trend) = 0.11), sTNF-R2 (OR = 1.9, 95% CI = 0.9-3.5, p (trend) = 0.06), and IL-5 (OR = 0.5, 95% CI = 0.3-1.0, p (trend) = 0.06).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Am J Epidemiol. 1999 Feb 15;149(4):372-8 [10025481.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1102-9 [15976097.001]
  • [Cites] J Reprod Immunol. 2005 Aug;66(2):175-91 [16029895.001]
  • [Cites] Neuroimmunomodulation. 2005;12(5):255-69 [16166805.001]
  • [Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Br J Haematol. 2006 May;133(3):293-300 [16643431.001]
  • [Cites] Blood. 2006 May 15;107(10):4101-8 [16449530.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):158-66 [17227999.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):117-22 [17087739.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • [Cites] Arch Intern Med. 2007 Aug 13-27;167(15):1676-85 [17698692.001]
  • [Cites] Am J Epidemiol. 2008 Jan 1;167(1):90-5 [17890755.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Immunol Methods. 2009 Oct 31;350(1-2):125-32 [19748508.001]
  • [Cites] Genes Immun. 1999 Nov;1(2):105-14 [11196656.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Eur J Immunol. 2000 Jun;30(6):1733-9 [10898511.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):243-55 [10986418.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Cytometry. 2001 Sep 1;45(1):27-36 [11598944.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5580-94 [11607811.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):37-45 [11905836.001]
  • [Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] Blood. 2004 May 1;103(9):3529-34 [14701701.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3085-90 [15353339.001]
  • [Cites] J Immunol. 1988 Jun 15;140(12):4224-30 [2453572.001]
  • [Cites] Breast Cancer Res Treat. 1991 May;18 Suppl 1:S23-6 [1873553.001]
  • [Cites] J Exp Med. 1992 Apr 1;175(4):973-82 [1552290.001]
  • [Cites] Lymphokine Cytokine Res. 1992 Jun;11(3):157-9 [1327192.001]
  • [Cites] Hum Pathol. 1993 Oct;24(10):1040-57 [8406414.001]
  • [Cites] Curr Opin Oncol. 1993 Sep;5(5):776-84 [8218489.001]
  • [Cites] J Immunol. 1993 Dec 1;151(11):6370-81 [7902377.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2253-60 [7919343.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1843-9 [7703491.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1717-25 [8637518.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1489-96 [9338474.001]
  • [Cites] Clin Immunol. 1999 Nov;93(2):114-23 [10527687.001]
  • (PMID = 20373009.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016087; United States / NCI NIH HHS / CA / CA098661-07; United States / NIEHS NIH HHS / ES / P30 ES000260; United States / NCI NIH HHS / CA / R01 CA098661-08; United States / NIEHS NIH HHS / ES / ES00260; United States / NCI NIH HHS / CA / R01 CA098661-06A2; United States / NCI NIH HHS / CA / R01 CA098661-07; United States / NCI NIH HHS / CA / R01 CA098661; United States / NCI NIH HHS / CA / R01 CA98661; United States / NCI NIH HHS / CA / CA098661-08; United States / NCI NIH HHS / CA / CA16087; United States / NCI NIH HHS / CA / CA098661-06A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS267470; NLM/ PMC3111139
  •  go-up   go-down


54. Spina M, Tirelli U: Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol; 2005 Sep;17(5):462-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
  • PURPOSE OF REVIEW: This review discusses the potential benefits and risks of using the anti-CD20 monoclonal antibody rituximab for the treatment of HIV-associated B-cell non-Hodgkin's lymphoma.
  • Several recently reported phase II and III trials have evaluated the use of rituximab plus chemotherapy for HIV-associated B-cell non-Hodgkin's lymphoma.
  • A phase III trial comparing CHOP with CHOP-plus rituximab (R-CHOP) demonstrated a lower risk from progression of the lymphoma, but a higher risk of early and late infectious-related death in patients with a low CD4 count (< 50/microL).
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093796.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 19
  •  go-up   go-down


55. Sirera G, Videla S, Piñol M, Cañadas MP, Llatjos M, Ballesteros AL, García-Cuyás F, Castellá E, Guerola R, Tural C, Rey-Joly C, Clotet B: High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS; 2006 May 12;20(8):1201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomavirus (HPV) types are associated with squamous cell cancers.
  • It is important to assess whether HPV is present in other body parts involved in sexual practices to establish a cancer prevention program.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691074.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Ferrer RA, Morrow KM, Fisher WA, Fisher JD: Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care; 2010 Aug;22(8):997-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This model asserts that microbicide adherence-related information, motivation, and behavioral skills are fundamental determinants of adherent microbicide utilization.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552466.001).
  • [ISSN] 1360-0451
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  •  go-up   go-down


62. Moorman J, Dong ZP, Ni L, Zhang C, Borthwick T, Yao ZQ: Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Immunology; 2009 Oct;128(2):227-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection.
  • Chronic hepatitis C virus (HCV) infection is associated with cirrhosis, autoimmunity and lymphoproliferative disorders.
  • Importantly, tumour necrosis factor- and Apo-L-related leucocyte-expressed ligand-1 (TALL-1), also known as B-lymphocyte stimulator (BLYS), was found to be up-regulated on the surface of B cells from HCV patients in response to PHA as well as HCV core antigen stimulation.
  • This up-regulation of TALL-1 was associated with vigorous memory B-cell responses to viral antigenic stimulation.
  • These findings suggest that TALL-1 over-expression and SOCS-1 suppression are associated with aberrant B-cell activation, providing a plausible basis for the B-cell clonal expansion underlying the lymphoproliferative disorders and autoimmune phenomena observed during chronic HCV infection.

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):191-4 [15121754.001]
  • [Cites] Eur J Clin Invest. 2003 Feb;33(2):161-8 [12588291.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7726-33 [15361843.001]
  • [Cites] Arthritis Rheum. 1991 Dec;34(12):1606-10 [1660716.001]
  • [Cites] Hepatology. 1995 Mar;21(3):613-9 [7533120.001]
  • [Cites] Br J Haematol. 1995 Jul;90(3):548-52 [7646992.001]
  • [Cites] J Rheumatol. 1996 Sep;23(9):1641-3 [8877939.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1375-9 [9397973.001]
  • [Cites] Ann Intern Med. 1998 Apr 15;128(8):695 [9537949.001]
  • [Cites] J Med Virol. 1998 May;55(1):1-6 [9580878.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):237-9 [9935205.001]
  • [Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]
  • [Cites] Science. 1999 Jul 9;285(5425):260-3 [10398604.001]
  • [Cites] Hepatology. 1999 Sep;30(3):822-3 [10490376.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3668-78 [15529359.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3370-5 [10716715.001]
  • [Cites] J Clin Invest. 2000 Nov;106(10):1239-49 [11086025.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):6-10 [11123269.001]
  • [Cites] Blood. 2001 Jan 1;97(1):198-204 [11133761.001]
  • [Cites] Arthritis Rheum. 2001 Jun;44(6):1313-9 [11407690.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):21-9 [11418627.001]
  • [Cites] J Virol. 2001 Sep;75(17):8240-50 [11483769.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):5264-72 [11673541.001]
  • [Cites] J Clin Invest. 2002 Jan;109(1):59-68 [11781351.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):410-6 [12093007.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2252-4; author reply 2254-5 [12209536.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • [Cites] Ann Rheum Dis. 2003 Feb;62(2):168-71 [12525388.001]
  • [Cites] J Rheumatol. 2003 Aug;30(8):1775-81 [12913934.001]
  • [Cites] AIDS. 2003 Sep 5;17(13):1983-5 [12960832.001]
  • [Cites] Virology. 2003 Sep 15;314(1):271-82 [14517080.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5215-24 [14607922.001]
  • [Cites] Lancet Infect Dis. 2005 Apr;5(4):227-36 [15792740.001]
  • [Cites] J Hepatol. 2005 May;42(5):632-8 [15826710.001]
  • [Cites] J Rheumatol. 2005 Jun;32(6):1164-7 [15940780.001]
  • [Cites] Clin Rheumatol. 2005 Sep;24(5):507-15 [15988558.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):192-201 [16385515.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2344-7 [16416186.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):194-202 [16082380.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):3931-41 [16547227.001]
  • [Cites] J Autoimmun. 2006 Sep;27(2):134-9 [17029886.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):37-43 [16735452.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):65-9 [16782735.001]
  • [Cites] Rev Med Chil. 2006 Sep;134(9):1175-84 [17171221.001]
  • [Cites] Viral Immunol. 2007 Summer;20(2):276-87 [17603844.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):3637-41 [18322167.001]
  • [Cites] Immunology. 2008 Oct;125(2):197-207 [18397267.001]
  • [Cites] J Virol. 2004 Jun;78(12):6409-19 [15163734.001]
  • (PMID = 19740379.001).
  • [ISSN] 1365-2567
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R15 AI072750; United States / NIAID NIH HHS / AI / R15AI072750
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / Hepatitis C Antigens; 0 / SOCS1 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2767312
  •  go-up   go-down


63. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U: AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res; 2009 Nov;7(6):634-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies.
  • In the HAART era Kaposi's sarcoma (KS) remains the second most frequent tumor in HIV-infected patients worldwide, and it has become the most common cancer in Sub-Saharan Africa.
  • KS lesions are comprised of both distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate, which suggests that KS may result from reactive hyperproliferation induced by chronic inflammation, and therefore it is not a true neoplasm.
  • Treatment decisions must take into consideration the extent and the rate of tumor growth, patient's symptoms, immune system conditions and concurrent HIV-related complications.
  • The aim of this article is to provide an up-to-date review of the current status and perspectives of AIDS-related KS in the HAART era.


64. López-Huertas MR, Callejas S, Abia D, Mateos E, Dopazo A, Alcamí J, Coiras M: Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res; 2010 Jun;38(10):3287-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Second, cytoskeleton-related functions as cell morphology, proliferation, chemotaxis, polarization and actin polymerization were deeply altered in Jurkat-Tat101, but not in Jurkat-Tat72.
  • Consequently, these modifications were greatly dependent on Tat second exon and they could be related to the anergy observed in HIV-1-infected T cells.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004;32(4):1270-8 [14981150.001]
  • [Cites] Eur J Clin Invest. 2004 Jan;34(1):57-66 [14984439.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14331-7 [14718541.001]
  • [Cites] PLoS Biol. 2004 Jan;2(1):E6 [14737186.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Mar;20(3):297-304 [15117453.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5193-202 [15122328.001]
  • [Cites] Virology. 2004 Aug 15;326(1):79-89 [15262497.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Mol Biol. 1993 Mar 5;230(1):90-110 [8450553.001]
  • [Cites] J Virol. 1993 Jul;67(7):3739-47 [8510203.001]
  • [Cites] Virology. 1993 Aug;195(2):826-30 [8337847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7941-5 [7690138.001]
  • [Cites] J Virol. 1993 Nov;67(11):6596-604 [8411362.001]
  • [Cites] J Biol Chem. 1993 Nov 25;268(33):24940-9 [8227056.001]
  • [Cites] J Mol Biol. 1993 Dec 5;234(3):779-815 [8254673.001]
  • [Cites] J Clin Invest. 1994 Jun;93(6):2505-13 [7515393.001]
  • [Cites] Nucleic Acids Res. 1994 Oct 25;22(21):4405-13 [7971271.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):546-54 [7859743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2026-30 [7892219.001]
  • [Cites] Ann Neurol. 1995 Mar;37(3):373-80 [7695237.001]
  • [Cites] J Virol. 1999 Mar;73(3):1956-63 [9971775.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1581-8 [10102628.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3645-53 [10207088.001]
  • [Cites] J Virol. 1999 Aug;73(8):7080-6 [10400814.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):28837-40 [10506122.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48197-204 [15331610.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:932-41 [15818415.001]
  • [Cites] Retrovirology. 2005;2:5 [15691386.001]
  • [Cites] Retrovirology. 2005;2:6 [15698475.001]
  • [Cites] New Microbiol. 2005 Apr;28(2):95-109 [16035254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16362-7 [16260749.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38376-82 [16155003.001]
  • [Cites] J Neurosci. 2006 Apr 12;26(15):4054-62 [16611822.001]
  • [Cites] Proteomics. 2006 Apr;6 Suppl 1:S63-73 [16526095.001]
  • [Cites] J Gen Virol. 2006 Jun;87(Pt 6):1603-12 [16690925.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34574-91 [16935861.001]
  • [Cites] Cell. 1986 Sep 26;46(7):1053-61 [3463433.001]
  • [Cites] J Cell Biol. 1977 Nov;75(2 Pt 1):593-605 [233748.001]
  • [Cites] EMBO J. 1988 Oct;7(10):3143-7 [3181132.001]
  • [Cites] J Virol. 1989 Mar;63(3):1181-7 [2536828.001]
  • [Cites] J Virol. 1989 Dec;63(12):5501-4 [2479775.001]
  • [Cites] Science. 1989 Dec 22;246(4937):1606-8 [2556795.001]
  • [Cites] J Virol. 1991 Feb;65(2):961-7 [1898974.001]
  • [Cites] Proteins. 1991;9(3):180-90 [2006136.001]
  • [Cites] Nature. 1991 Apr 25;350(6320):709-12 [2023633.001]
  • [Cites] J Virol. 1991 Jul;65(7):3460-7 [1645777.001]
  • [Cites] J Virol. 1992 Jun;66(6):3883-7 [1583734.001]
  • [Cites] J Exp Med. 1992 Sep 1;176(3):739-50 [1512539.001]
  • [Cites] Eur J Immunol. 1992 Oct;22(10):2729-32 [1396975.001]
  • [Cites] Nucleic Acids Res. 1992 Oct 25;20(20):5465-72 [1437564.001]
  • [Cites] J Virol. 1993 Jan;67(1):277-87 [8416373.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2917-23 [8428966.001]
  • [Cites] J Immunol. 1993 Mar 15;150(6):2544-53 [8095514.001]
  • [Cites] Science. 1995 Apr 21;268(5209):429-31 [7716549.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1552-60 [7729429.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):497-500 [7539892.001]
  • [Cites] Exp Cell Res. 1995 Jul;219(1):180-96 [7628534.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;193:51-77 [7648878.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Sep;11(9):1039-48 [8554901.001]
  • [Cites] Annu Rev Immunol. 1996;14:591-617 [8717526.001]
  • [Cites] Med Hypotheses. 1995 Nov;45(5):486-90 [8748093.001]
  • [Cites] J Virol. 1996 Nov;70(11):7734-43 [8892894.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):1014-9 [8993024.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):551-60 [9031086.001]
  • [Cites] J Virol. 1997 Mar;71(3):2495-9 [9032389.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2107-15 [9036955.001]
  • [Cites] Science. 1997 Mar 7;275(5305):1481-5 [9045614.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1224-35 [9135139.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13803-9 [9153236.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] J Cell Biol. 1997 Sep 22;138(6):1409-23 [9298994.001]
  • [Cites] Eur J Immunol. 1997 Nov;27(11):2805-11 [9394803.001]
  • [Cites] J Exp Med. 1998 Mar 16;187(6):875-83 [9500790.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):384-9 [9514931.001]
  • [Cites] J Virol. 1998 Jul;72(7):6113-8 [9621075.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jun;57(6):563-70 [9630236.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13153-8 [9789057.001]
  • [Cites] AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1553-9 [9840288.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] J Leukoc Biol. 2008 Mar;83(3):718-27 [